



(11)

EP 1 268 481 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
12.12.2007 Bulletin 2007/50

(21) Application number: **00963510.3**

(22) Date of filing: **15.09.2000**

(51) Int Cl.:

C07D 487/04 <small>(2006.01)</small>	C07D 471/04 <small>(2006.01)</small>
C07D 491/04 <small>(2006.01)</small>	C07D 498/04 <small>(2006.01)</small>
A61K 31/519 <small>(2006.01)</small>	A61K 31/5025 <small>(2006.01)</small>
A61K 31/4353 <small>(2006.01)</small>	A61K 31/551 <small>(2006.01)</small>
A61P 35/00 <small>(2006.01)</small>	C07D 487/04 <small>(2006.01)</small>
C07D 239/00 <small>(2006.01)</small>	C07D 209/00 <small>(2006.01)</small>
C07D 487/04 <small>(2006.01)</small>	C07D 237/00 <small>(2006.01)</small>
C07D 209/00 <small>(2006.01)</small>	C07D 471/04 <small>(2006.01)</small>
C07D 231/00 <small>(2006.01)</small>	C07D 221/00 <small>(2006.01)</small>
C07D 487/04 <small>(2006.01)</small>	C07D 243/00 <small>(2006.01)</small>
C07D 239/00 <small>(2006.01)</small>	

(86) International application number:
PCT/US2000/025357

(87) International publication number:
WO 2001/019828 (22.03.2001 Gazette 2001/12)

(54) **KINASE INHIBITORS AS THERAPEUTIC AGENTS**

KINASEINHIBITOREN ALS ARZNEIMITTEL

INHIBITEURS DE KINASE UTILISES COMME AGENTS THERAPEUTIQUES

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: **17.09.1999 US 154618 P**

(43) Date of publication of application:
02.01.2003 Bulletin 2003/01

(73) Proprietor: **Abbott GmbH & Co. KG
65205 Wiesbaden (DE)**

(72) Inventors:
• **HIRST, Gavin, C.
Marlboro, MA 01752 (US)**
• **RITTER, Kurt
65926 Frankfurt (DE)**
• **RAFFERTY, Paul
Westborough, MA 01581 (US)**

- **ST.GALLAY, Stephen
Loughborough,
Leics. LE11 5RH (GB)**
- **CALDERWOOD, David
Framingham, MA 01702 (US)**
- **TWIGGER, Helen, L.
Nottingham, NG1 1GF (GB)**

(74) Representative: **Modiano, Micaela Nadia et al
Modiano Josif Pisanty & Staub Ltd
Thierschstrasse 11
80538 München (DE)**

(56) References cited:
WO-A-00/44728 WO-A-98/41525

Remarks:

The file contains technical information submitted after
the application was filed and not included in this
specification

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

Description

[0001] There are at least 400 enzymes identified as protein kinases. These enzymes catalyze the phosphorylation of target protein substrates. The phosphorylation is usually a transfer reaction of a phosphate group from ATP to the protein substrate. The specific structure in the target substrate to which the phosphate is transferred is a tyrosine, serine or threonine residue. Since these amino acid residues are the target structures for the phosphoryl transfer, these protein kinase enzymes are commonly referred to as tyrosine kinases or serine/threonine kinases.

[0002] The phosphorylation reactions, and counteracting phosphatase reactions, at the tyrosine, serine and threonine residues are involved in countless cellular processes that underlie responses to diverse intracellular signals (typically mediated through cellular receptors), regulation of cellular functions, and activation or deactivation of cellular processes. A cascade of protein kinases often participate in intracellular signal transduction and are necessary for the realization of these cellular processes. Because of their ubiquity in these processes, the protein kinases can be found as an integral part of the plasma membrane or as cytoplasmic enzymes or localized in the nucleus, often as components of enzyme complexes. In many instances, these protein kinases are an essential element of enzyme and structural protein complexes that determine where and when a cellular process occurs within a cell.

[0003] *Protein Tyrosine Kinases.* Protein tyrosine kinases (PTKs) are enzymes which catalyse the phosphorylation of specific tyrosine residues in cellular proteins. This post-translational modification of these substrate proteins, often enzymes themselves, acts as a molecular switch regulating cell proliferation, activation or differentiation (for review, see Schlessinger and Ulrich, 1992, *Neuron* 9:383-391). Aberrant or excessive PTK activity has been observed in many disease states including benign and malignant proliferative disorders as well as diseases resulting from inappropriate activation of the immune system (e.g., autoimmune disorders), allograft rejection, and graft vs. host disease. In addition, endothelial-cell specific receptor PTKs such as KDR and Tie-2 mediate the angiogenic process, and are thus involved in supporting the progression of cancers and other diseases involving inappropriate vascularization (e.g., diabetic retinopathy, choroidal neovascularization due to age-related macular degeneration, psoriasis, arthritis, retinopathy of prematurity, infantile hemangiomas).

[0004] Tyrosine kinases can be of the receptor-type (having extracellular, transmembrane and intracellular domains) or the non-receptor type (being wholly intracellular).

[0005] *Receptor Tyrosine Kinases (RTKs).* The RTKs comprise a large family of transmembrane receptors with diverse biological activities. At present, at least nineteen (19) distinct RTK subfamilies have been identified. The

receptor tyrosine kinase (RTK) family includes receptors that are crucial for the growth and differentiation of a variety of cell types (Yarden and Ullrich, *Ann. Rev. Biochem.* 57:433-478, 1988; Ullrich and Schlessinger, *Cell* 61:243-254, 1990). The intrinsic function of RTKs is activated upon ligand binding, which results in phosphorylation of the receptor and multiple cellular substrates, and subsequently in a variety of cellular responses (Ullrich & Schlessinger, 1990, *Cell* 61:203-212). Thus, receptor tyrosine kinase mediated signal transduction is initiated by extracellular interaction with a specific growth factor (ligand), typically followed by receptor dimerization, stimulation of the intrinsic protein tyrosine kinase activity and receptor transphosphorylation. Binding sites are thereby created for intracellular signal transduction molecules and lead to the formation of complexes with a spectrum of cytoplasmic signaling molecules that facilitate the appropriate cellular response. (e.g., cell division, differentiation, metabolic effects, changes in the extracellular microenvironment) see Schlessinger and Ullrich, 1992, *Neuron* 9:1-20.

[0006] Proteins with SH2 (src homology -2) or phosphotyrosine binding (PTB) domains bind activated tyrosine kinase receptors and their substrates with high affinity to propagate signals into cell. Both of the domains recognize phosphotyrosine. (Fantl et al., 1992, *Cell* 69:413-423; Songyang et al., 1994, *Mol. Cell. Biol.* 14:2777-2785; Songyang et al., 1993, *Cell* 72:767-778; and Koch et al., 1991, *Science* 252:668-678; Shoelson, *Curr. Opin. Chem. Biol.* (1997), 1(2), 227-234; Cowburn, *Curr. Opin. Struct. Biol.* (1997), 7(6), 835-838). Several intracellular substrate proteins that associate with receptor tyrosine kinases (RTKs) have been identified. They may be divided into two principal groups: (1) substrates which have a catalytic domain; and (2) substrates which lack such a domain but serve as adapters and associate with catalytically active molecules (Songyang et al., 1993, *Cell* 72:767-778). The specificity of the interactions between receptors or proteins and SH2 or PTB domains of their substrates is determined by the amino acid residues immediately surrounding the phosphorylated tyrosine residue. For example, differences in the binding affinities between SH2 domains and the amino acid sequences surrounding the phosphotyrosine residues on particular receptors correlate with the observed differences in their substrate phosphorylation profiles (Songyang et al., 1993, *Cell* 72:767-778). Observations suggest that the function of each receptor tyrosine kinase is determined not only by its pattern of expression and ligand availability but also by the array of downstream signal transduction pathways that are activated by a particular receptor as well as the timing and duration of those stimuli. Thus, phosphorylation provides an important regulatory step which determines the selectivity of signaling pathways recruited by specific growth factor receptors, as well as differentiation factor receptors.

[0007] Several receptor tyrosine kinases such as FGFR-1, PDGFR, TIE-2 and c-Met, and growth factors that

bind thereto, have been suggested to play a role in angiogenesis, although some may promote angiogenesis indirectly (Mustonen and Alitalo, J. Cell Biol. 129: 895-898, 1995). One such receptor tyrosine kinase, known as "fetal liver kinase 1" (FLK-1), is a member of the type III subclass of RTKs. An alternative designation for human FLK-1 is "kinase insert domain-containing receptor" (KDR) (Terman et al., Oncogene 6:1677-83, 1991). Another alternative designation for FLK-1/KDR is "vascular endothelial cell growth factor receptor 2" (VEGFR-2) since it binds VEGF with high affinity. The murine version of FLK-1/VEGFR-2 has also been called NYK (Oelrichs et al., Oncogene 8(1):11-15, 1993). DNAs encoding mouse, rat and human FLK-1 have been isolated, and the nucleotide and encoded amino acid sequences reported (Matthews et al., Proc. Natl. Acad. Sci. USA, 88: 9026-30, 1991; Terman et al., 1991, *supra*; Terman et al., Biochem. Biophys. Res. Comm. 187:1579-86, 1992; Sarzani et al., *supra*; and Millauer et al., Cell 72:835-846, 1993). Numerous studies such as those reported in Millauer *et al.*, *supra*, suggest that VEGF and FLK-1/KDR/VEGFR-2 are a ligand-receptor pair that play an important role in the proliferation of vascular endothelial cells, and formation and sprouting of blood vessels, termed vasculogenesis and angiogenesis, respectively.

[0008] Another type III subclass RTK designated "fms-like tyrosine kinase-1" (Flt-1) is related to FLK-1/KDR (DeVries et al. Science 255:989-991, 1992; Shibuya et al., Oncogene 5:519-524, 1990). An alternative designation for Flt-1 is "vascular endothelial cell growth factor receptor 1" (VEGFR-1). To date, members of the FLK-1/KDR/VEGFR-2 and Flt-1/VEGFR-1 subfamilies have been found expressed primarily on endothelial cells. These subclass members are specifically stimulated by members of the vascular endothelial cell growth factor (VEGF) family of ligands (Klagsburn and D'Amore, Cytokine & Growth Factor Reviews 7: 259-270, 1996). Vascular endothelial cell growth factor (VEGF) binds to Flt-1 with higher affinity than to FLK-1/KDR and is mitogenic toward vascular endothelial cells (Terman et al., 1992, *supra*; Mustonen et al. *supra*; DeVries et al., *supra*). Flt-1 is believed to be essential for endothelial organization during vascular development. Flt-1 expression is associated with early vascular development in mouse embryos, and with neovascularization during wound healing (Mustonen and Alitalo, *supra*). Expression of Flt-1 in monocytes, osteoclasts, and osteoblasts, as well as in adult tissues such as kidney glomeruli suggests an additional function for this receptor that is not related to cell growth (Mustonen and Alitalo, *supra*).

[0009] As previously stated, recent evidence suggests that VEGF plays a role in the stimulation of both normal and pathological angiogenesis (Jakeman et al., Endocrinology 133: 848-859, 1993; Kolch et al., Breast Cancer Research and Treatment 36: 139-155, 1995; Ferrara et al., Endocrine Reviews 18(1): 4-25, 1997; Ferrara et al., Regulation of Angiogenesis (ed. L. D. Goldberg and E.M. Rosen), 209-232, 1997). In addition, VEGF has been im-

plicated in the control and enhancement of vascular permeability (Connolly, et al., J. Biol. Chem. 264: 20017-20024, 1989; Brown et al., Regulation of Angiogenesis (ed. L.D. Goldberg and E.M. Rosen), 233-269, 1997). Different forms of VEGF arising from alternative splicing of mRNA have been reported, including the four species described by Ferrara et al. (J. Cell. Biochem. 47: 211-218, 1991). Both secreted and predominantly cell-associated species of VEGF have been identified by Ferrara *et al. supra*, and the protein is known to exist in the form of disulfide linked dimers.

[0010] Several related homologs of VEGF have recently been identified. However, their roles in normal physiological and disease processes have not yet been elucidated. In addition, the members of the VEGF family are often coexpressed with VEGF in a number of tissues and are, in general, capable of forming heterodimers with VEGF. This property likely alters the receptor specificity and biological effects of the heterodimers and further complicates the elucidation of their specific functions as illustrated below (Korpelainen and Alitalo, Curr. Opin. Cell Biol., 159-164, 1998 and references cited therein).

[0011] Placenta growth factor (P1GF) has an amino acid sequence that exhibits significant homology to the VEGF sequence (Park et al., J. Biol. Chem. 269: 25646-54, 1994; Maglione et al. Oncogene 8:925-31, 1993). As with VEGF, different species of P1GF arise from alternative splicing of mRNA, and the protein exists in dimeric form (Park *et al.*, *supra*). P1GF-1 and P1GF-2 bind to Flt-1 with high affinity, and P1GF-2 also avidly binds to neuropilin-1 (Migdal et al, J. Biol. Chem. 273 (35): 22272-22278), but neither binds to FLK-1/KDR (Park *et al.*, *supra*). P1GF has been reported to potentiate both the vascular permeability and mitogenic effect of VEGF on endothelial cells when VEGF is present at low concentrations (purportedly due to heterodimer formation) (Park *et al.*, *supra*).

[0012] VEGF-B is produced as two isoforms (167 and 185 residues) that also appear to bind Flt-1/VEGFR-1. It may play a role in the regulation of extracellular matrix degradation, cell adhesion, and migration through modulation of the expression and activity of urokinase type plasminogen activator and plasminogen activator inhibitor 1 (Pepper et al, Proc. Natl. Acad. Sci. U. S. A. (1998), 95(20): 11709-11714).

[0013] VEGF-C was originally cloned as a ligand for VEGFR-3/Flt-4 which is primarily expressed by lymphatic endothelial cells. In its fully processed form, VEGF-C can also bind KDR/VEGFR-2 and stimulate proliferation and migration of endothelial cells *in vitro* and angiogenesis in *in vivo* models (Lymboussaki et al, Am. J. Pathol. (1998), 153(2): 395-403; Witzenbichler et al, Am. J. Pathol. (1998), 153(2), 381-394). The transgenic overexpression of VEGF-C causes proliferation and enlargement of only lymphatic vessels, while blood vessels are unaffected. Unlike VEGF, the expression of VEGF-C is not induced by hypoxia (Ristimaki et al, J. Biol. Chem. (1998), 273(14), 8413-8418).

[0014] The most recently discovered VEGF-D is structurally very similar to VEGF-C. VEGF-D is reported to bind and activate at least two VEGFRs, VEGFR-3/Flt-4 and KDR/VEGFR-2. It was originally cloned as a c-fos inducible mitogen for fibroblasts and is most prominently expressed in the mesenchymal cells of the lung and skin (Achen et al, Proc. Natl. Acad. Sci. U. S. A. (1998), 95 (2), 548-553 and references therein).

[0015] As for VEGF, VEGF-C and VEGF-D have been claimed to induce increases in vascular permeability *in vivo* in a Miles assay when injected into cutaneous tissue (PCT/US97/14696; WO98/07832, Witzembichler et al., *supra*). The physiological role and significance of these ligands in modulating vascular hyperpermeability and endothelial responses in tissues where they are expressed remains uncertain.

[0016] There has been recently reported a virally encoded, novel type of vascular endothelial growth factor, VEGF-E (NZ-7 VEGF), which preferentially utilizes KDR/Flk-1 receptor and carries a potent mitotic activity without heparin-binding domain (Meyer et al, EMBO J. (1999), 18(2), 363-374; Ogawa et al, J. Biol. Chem. (1998), 273(47), 31273-31282.). VEGF-E sequences possess 25% homology to mammalian VEGF and are encoded by the parapoxvirus Orf virus (OV). This parapoxvirus that affects sheep and goats and occasionally, humans, to generate lesions with angiogenesis. VEGF-E is a dimer of about 20 kDa with no basic domain nor affinity for heparin, but has the characteristic cysteine knot motif present in all mammalian VEGFs, and was surprisingly found to possess potency and bioactivities similar to the heparin-binding VEGF165 isoform of VEGF-A, i.e. both factors stimulate the release of tissue factor (TF), the proliferation, chemotaxis and sprouting of cultured vascular endothelial cells *in vitro* and angiogenesis *in vivo*. Like VEGF165, VEGF-E was found to bind with high affinity to VEGF receptor-2 (KDR) resulting in receptor autophosphorylation and a biphasic rise in free intracellular Ca²⁺ concentrations, while in contrast to VEGF165, VEGF-E did not bind to VEGF receptor-1 (Flt-1).

[0017] Based upon emerging discoveries of other homologs of VEGF and VEGFRs and the precedents for ligand and receptor heterodimerization, the actions of such VEGF homologs may involve formation of VEGF ligand heterodimers, and/or heterodimerization of receptors, or binding to a yet undiscovered VEGFR (Witzembichler et al., *supra*). Also, recent reports suggest neuropilin-1 (Migdal et al, *supra*) or VEGFR-3/Flt-4 (Witzembichler et al., *supra*), or receptors other than KDR/VEGFR-2 may be involved in the induction of vascular permeability (Stacker, S.A., Vitali, A., Domagala, T., Nice, E., and Wilks, A.F., "Angiogenesis and Cancer" Conference, Amer. Assoc. Cancer Res., Jan. 1998, Orlando, FL; Williams, Diabetologia 40: S118-120 (1997)). Until now, no direct evidence for the essential role of KDR in VEGF-mediated vascular hyperpermeability has been disclosed.

[0018] *The Non-Receptor Tyrosine Kinases.* The non-receptor tyrosine kinases represent a collection of cellular enzymes which lack extracellular and transmembrane sequences. At present, over twenty-four individual non-receptor tyrosine kinases, comprising eleven (11) sub-families (Src, Frk, Btk, Csk, Abl, Zap70, Fes/Fps, Fak, Jak, Ack and LIMK) have been identified. At present, the Src subfamily of non-receptor tyrosine kinases is comprised of the largest number of PTKs and include Src, Yes, Fyn, Lyn, Lck, Blk, Hck, Fgr and Yrk. The Src subfamily of enzymes has been linked to oncogenesis and immune responses. A more detailed discussion of non-receptor tyrosine kinases is provided in Bolen, 1993, Oncogene 8:2025-2031, which is incorporated herein by reference.

[0019] Many of the tyrosine kinases, whether an RTK or non-receptor tyrosine kinase, have been found to be involved in cellular signaling pathways involved in numerous pathogenic conditions, including cancer, psoriasis, and other hyperproliferative disorders or hyper-immune responses.

[0020] *Development of Compounds to Modulate the PTKs.* In view of the surmised importance of PTKs to the control, regulation, and modulation of cell proliferation, the diseases and disorders associated with abnormal cell proliferation, many attempts have been made to identify receptor and non-receptor tyrosine kinase "inhibitors" using a variety of approaches, including the use of mutant ligands (U.S. Application No. 4,966,849), soluble receptors and antibodies (Application No. WO 94/10202; Kendall & Thomas, 1994, Proc. Natl. Acad. Sci 90:10705-09; Kim et al., 1993, Nature 362:841-844), RNA ligands (Jellinek, et al., Biochemistry 33:10450-56; Takano, et al., 1993, Mol. Bio. Cell 4:358A; Kinsella, et al. 1992, Exp. Cell Res. 199:56-62; Wright, et al., 1992, J. Cellular Phys. 152:448-57) and tyrosine kinase inhibitors (WO 94/03427; WO 92/21660; WO 91/15495; WO 94/14808; U.S. Patent No. 5,330,992; Mariani, et al., 1994, Proc. Am. Assoc. Cancer Res. 35:2268).

[0021] More recently, attempts have been made to identify small molecules which act as tyrosine kinase inhibitors. For example, bis monocyclic, bicyclic or heterocyclic aryl compounds (PCT WO 92/20642) and vinylene-azaindole derivatives (PCT WO 94/14808) have been described generally as tyrosine kinase inhibitors. Styryl compounds (U.S. Patent No. 5,217,999), styryl-substituted pyridyl compounds (U.S. Patent No. 5,302,606), certain quinazoline derivatives (EP Application No. 0 566 266 A1; Expert Opin. Ther. Pat. (1998), 8(4): 475-478), selenoindoles and selenides (PCT WO 94/03427), tricyclic polyhydroxylic compounds (PCT WO 92/21660) and benzylphosphonic acid compounds (PCT WO 91/15495) have been described as compounds for use as tyrosine kinase inhibitors for use in the treatment of cancer. Anilinoquinolines (PCT WO97/34876) and quinazoline derivative compounds (PCT WO97/22596; PCT WO97/42187) have been described as inhibitors of angiogenesis and vascular permeability.

[0022] In addition, attempts have been made to identify small molecules which act as serine/threonine kinase inhibitors. For example, bis(indolylmaleimide) compounds have been described as inhibiting particular PKC serine/threonine kinase isoforms whose signal transducing function is associated with altered vascular permeability in VEGF-related diseases (PCT WO97/40830; PCT WO97/40831).

Plk-1 Kinase Inhibitors

[0023] Plk-1 is a serine/threonine kinase which is an important regulator of cell cycle progression. It plays critical roles in the assembly and the dynamic function of the mitotic spindle apparatus. Plk-1 and related kinases have also been shown to be closely involved in the activation and inactivation of other cell cycle regulators, such as cyclin-dependent kinases. High levels of Plk-1 expression are associated with cell proliferation activities. It is often found in malignant tumors of various origins. Inhibitors of Plk-1 are expected to block cancer cell proliferation by disrupting processes involving mitotic spindles and inappropriately activated cyclin-dependent kinases.


Cdc2/Cyclin B Kinase Inhibitors (Cdc2 is also known as cdkl)

[0024] Cdc2/cyclin B is another serine/threonine kinase enzyme which belongs to the cyclin-dependent kinase (cdks) family. These enzymes are involved in the critical transition between various phases of cell cycle progression. It is believed that uncontrolled cell proliferation, which is the hallmark of cancer is dependent upon elevated cdk activities in these cells. The inhibition of elevated cdk activities in cancer cells by cdc2/cyclin B kinase inhibitors could suppress proliferation and may restore the normal control of cell cycle progression.

[0025] The identification of effective small compounds which specifically inhibit signal transduction and cellular proliferation by modulating the activity of receptor and non-receptor tyrosine and serine/threonine kinases to regulate and modulate abnormal or inappropriate cell proliferation, differentiation, or metabolism is therefore desirable. In particular, the identification of methods and compounds that specifically inhibit the function of a tyrosine kinase which is essential for antiogenic processes or the formation of vascular hyperpermeability leading to edema, ascites, effusions, exudates, and macromolecular extravasation and matrix deposition as well as associated disorders would be beneficial.


SUMMARY OF THE INVENTION

[0026] The present invention provides a compound of Formula (I), the racemic-diastereomeric mixtures, optical isomers or pharmaceutically-acceptable salts thereof,



wherein:

R₁ is



Z¹⁰⁰ is an optionally substituted phenyl,

where Z¹⁰⁰ is optionally substituted with one or more substituents each independently selected from the group consisting of F, C1, CN, NO₂, - optionally substituted alkyl, -O-(optionally substituted alkyl), -C(O)H, -CONH₂, -NHSO₂CF₃, optionally substituted heteroaryl COOH, -Z¹⁰⁵-C(O)N(R)₂, -Z¹⁰⁵-N(R)-C(O)-Z²⁰⁰, -Z¹⁰⁵-N(R)-S(O)₂-Z²⁰⁰, and -Z¹⁰⁵-N(R)-C(O)-N(R)-Z²⁰⁰; Z¹⁰⁵ is a covalent bond or (C₁-C₆); Z²⁰⁰ is an optionally substituted group selected from group consisting of (C₁-C₆), phenyl and -(C₁-C₆)-phenyl;

Z¹¹⁰ and Z¹¹¹ are each independently a covalent bond and

A is O;

R_a is hydrogen;

R₃ is H;

R₂ is -Z¹⁰¹-Z¹⁰²;

Z¹⁰¹ is a covalent bond,

Z¹⁰² is a substituted or unsubstituted cycloalkyl group

[0027] The compounds of this invention are useful as inhibitors of serine/threonine and tyrosine kinases. In particular, compounds of this invention are useful as inhibitors of tyrosine kinases that are important in hyperproliferative diseases, especially in cancer and in the proc-

ess of angiogenesis. For example, certain of these compounds are inhibitors of such receptor kinases as KDR, Flt-1, FGFR, PDGFR, c-Met, TIE-2 or IGF-1-R.

[0028] Certain compounds of the invention are effective as inhibitors of serine/threonine kinases.

[0029] In addition, certain compounds are effective inhibitors of non-receptor kinases such as those of the Src (for example, lck, blk and lyn), family.

[0030] The present invention provides a method of inhibiting the kinase activity of tyrosine kinases and serine/threonine kinases comprising the administration of a compound represented by formula: I to said kinase in sufficient concentration to inhibit the enzyme activity of said kinase.

[0031] The present invention further includes the use of these compounds in pharmaceutical compositions with a pharmaceutically effective amount of the above-described compounds and a pharmaceutically acceptable carrier or excipient.


DETAILED DESCRIPTION OF THE INVENTION

[0032] Progression through the eukaryotic cell cycle is controlled by a family of kinases called cyclin dependent kinases (CDKs) (Myerson et al., EMBO Journal, 11: 2909-2917 (1992)). The regulation of CDK activation is complex, but requires the association of the CDK with a member of the cyclin family of regulatory subunits (Draetta, Trends in Cell Biology, 3:287-289 (1993)); Murray and Kirschner, Nature, 339:275-280 (1989); Solomon et al., Molecular Biology of the Cell, 3:13-27 (1992)). A further level of regulation occurs through both activating and inactivating phosphorylations of the CDK subunit (Draetta, Trends in Cell Biology, 3:287-289 (1993)); Murray and Kirschner, Nature, 339:275-280 (1989); Solomon et al., Molecular Biology of the Cell, 3:13-27 (1992); Ducommun et al., EMBO Journal, 10:3311-3319 (1991); Gautier et al., Nature 339:626-629 (1989); Gould and Nurse, Nature, 342:39-45 (1989); Krek and Nigg, EMBO Journal, 10:3331-3341 (1991); Solomon et al., Cell, 63: 1013-1024 (1990)). The coordinate activation and inactivation of different cyclin/CDK complexes is necessary for normal progression through the cell cycle (Pines, Trends in Biochemical Sciences, 18:195-197 (1993); Sherr, Cell, 73:1059-1065 (1993)). Both the critical G1-S and G2-M transitions are controlled by the activation of different cyclin/CDK activities. In G1, both cyclin D/CDK4 and cyclin E/CDK2 are thought to mediate the onset of S-phase (Matsushima et al., Molecular & Cellular Biology, 14:2066-2076 (1994); Ohtsubo and Roberts, Science, 259:1908-1912 (1993); Quelle et al., Genes & Development, 7:1559-1571 (1993); Resnitzky et al., Molecular & Cellular Biology, 14:1669-1679 (1994)). Progression through S-phase requires the activity of cyclin A/CDK2 (Girard et al., Cell, 67:1169-1179 (1991); Pagano et al., EMBO Journal, 11:961-971 (1992); Rosenblatt et al., Proceedings of the National Academy of Science USA, 89:2824-2828 (1992); Walker and Maller, Nature,

354:314-317 (1991); Zindy et al., Biochemical & Biophysical Research Communications, 182:1144-1154 (1992)) whereas the activation of cyclin A/cdc2 (CDK1) and cyclin B/cdc2 are required for the onset of metaphase (Draetta, Trends in Cell Biology, 3:287-289 (1993)); Murray and Kirschner, Nature, 339:275-280 (1989); Solomon et al., Molecular Biology of the Cell, 3:13-27 (1992); Girard et al., Cell, 67:1169-1179 (1991); Pagano et al., EMBO Journal, 11:961-971 (1992); Rosenblatt et al., Proceedings of the National Academy of Science USA, 89: 2824-2828 (1992); Walker and Maller, Nature, 354: 314-317 (1991); Zindy et al., Biochemical & Biophysical Research Communications, 182:1144-1154 (1992)). It is not surprising, therefore, that the loss of control of CDK regulation is a frequent event in hyperproliferative diseases and cancer. (Pines, Current Opinion in Cell Biology, 4:144-148 (1992); Lees, Current Opinion in Cell Biology, 7:773-780 (1995); Hunter and Pines, Cell, 79: 573-582 (1994)). The selective inhibition of CDKs is therefore an object of the present invention.

[0033] In a subset of compounds of Formula (I), R_3 is H;

R_2 is cyclopentyl; and
 R_1 is



[0034] In another subset of compounds of Formula (I), Z^{110} is a covalent bond A is O; and Z^{100} is optionally substituted phenyl, where Z^{100} is optionally substituted with one or more substituents each independently selected from the group consisting of F, COOH, NO₂, OMe, -COOMe, OCF₃ and CF₃.

[0035] In another subset of compounds of Formula (1), Z^{110} is a covalent bond A is -O-, Z^{100} is an optionally substituted phenyl, where Z^{100} is optionally substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halo, hydroxy and alkoxycarbonyl.

[0036] In another subset of compounds of Formula (I), R^2 is an optionally substituted group selected from the group consisting of cyclobutyl and cyclohexyl.

[0037] In another subset of compounds of Formula (I), R^2 is optionally substituted with one or more substituents selected from the group consisting of hydroxy, alkyl, hydroxyalkyl, carboxyalkyl and phenylalkoxyalkyl.

[0038] In another subset of compounds of Formula (I), R_1 is 4-phenoxyphenyl.

[0039] A subset of compounds of formula I have R_1 = 4-phenoxyphenyl, R_2 = cyclopentyl and both R_3 = H.

[0040] Compounds of formula I may exist as salts with pharmaceutically acceptable acids. The present inven-

tion includes such salts. Examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates [eg (+)-tartrates, (-)-tartrates or mixtures thereof including racemic mixtures], succinates, benzoates and salts with amino acids such as glutamic acid. These salts may be prepared by methods known to those skilled in the art.

[0041] Certain compounds of formula I which have acidic substituents may exist as salts with pharmaceutically acceptable bases. The present invention includes such salts. Example of such salts include sodium salts, potassium salts, lysine salts and arginine salts. These salts may be prepared by methods known to those skilled in the art.

[0042] Certain compounds of formula I and their salts may exist in more than one crystal form and the present invention includes each crystal form and mixtures thereof.

[0043] Certain compounds of formula I and their salts may also exist in the form of solvates, for example hydrates, and the present invention includes each solvate and mixtures thereof.

[0044] Certain compounds of formula I may contain one or more chiral centres, and exist in different optically active forms. When compounds of formula I contain one chiral centre, the compounds exist in two enantiomeric forms and the present invention includes both enantiomers and mixtures of enantiomers, such as racemic mixtures. The enantiomers may be resolved by methods known to those skilled in the art, for example by formation of diastereoisomeric salts which may be separated, for example, by crystallization; formation of diastereoisomeric derivatives or complexes which may be separated, for example, by crystallization, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, for example enzymatic esterification; or gas-liquid or liquid chromatography in a chiral environment, for example on a chiral support for example silica with a bound chiral ligand or in the presence of a chiral solvent. It will be appreciated that where the desired enantiomer is converted into another chemical entity by one of the separation procedures described above, a further step is required to liberate the desired enantiomeric form. Alternatively, specific enantiomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer into the other by asymmetric transformation.

[0045] When a compound of formula I contains more than one chiral centre it may exist in diastereoisomeric forms. The diastereoisomeric pairs may be separated by methods known to those skilled in the art, for example chromatography or crystallization and the individual enantiomers within each pair may be separated as described above. The present invention includes each diastereoisomer of compounds of formula I and mixtures thereof.

[0046] Certain compounds of formula I may exist in different tautomeric forms or as different geometric isomers, and the present invention includes each tautomer and/or geometric isomer of compounds of formula I and mixtures thereof.

[0047] Certain compounds of formula I may exist in different stable conformational forms which may be separable. Torsional asymmetry due to restricted rotation about an asymmetric single bond, for example because of steric hindrance or ring strain, may permit separation of different conformers. The present invention includes each conformational isomer of compounds of formula I and mixtures thereof.

[0048] Certain compounds of formula I may exist in zwitterionic form and the present invention includes each zwitterionic form of compounds of formula I and mixtures thereof. Heteroaromatic groups, as used herein, include heteroaryl ring systems (e.g., for purposes of exemplification, which should not be construed as limiting the scope of this invention: thienyl, pyridyl, pyrazole, isoxazolyl, thiadiazolyl, oxadiazolyl, indazolyl, furans, pyrroles, imidazoles, pyrazoles, triazoles, pyrimidines, pyrazines, thiazoles, isothiazoles, oxazolyl or tetrazoles) and heteroaryl ring systems in which a carbocyclic aromatic ring, carbocyclic nonaromatic ring or heteroaryl ring is fused to one or more other heteroaryl rings (e.g., for purposes of exemplification, which should not be construed as limiting the scope of this invention: benzo(b)thienyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzoxadiazolyl, indole, tetrahydroindole, azaindole, indazole, quinoline, imidazopyridine, quinoxaline, purine, pyrrolo[2,3-d]pyrimidine, pyrazolo[3,4-d]pyrimidine) and their N-oxides. Substituted heteroaryl groups are preferably substituted with one or more substituents each independently selected from the group consisting of a halogen, hydroxy, alkyl, alkoxy, alkyl-O-C(O)-, alkoxyalkyl, a heterocycloalkyl group, optionally substituted phenyl, nitro, amino, mono-substituted amino or di-substituted amino.

[0049] As used herein, many moieties or substituents are termed as being either "substituted or unsubstituted" or "optionally substituted". When a moiety is modified by one of these terms, it denotes that any portion of the moiety that is known to one skilled in the art as being available for substitution can be substituted, which includes one or more substituents; where if more than one substituent then each substituent is independently selected. Such means for substitution are well-known in the art and/or taught by the instant disclosure. For purposes of exemplification, which should not be construed as limiting the scope of this invention, some examples of groups that are substituents are: alkyl groups (which itself can also be substituted, such as CF₃), alkoxy group (which itself can be substituted, such as OCF₃), a halogen or halo group (F, Cl, Br, I), hydroxy, nitro, oxo, CN, COH, COOH, amino, N-alkylamino or N,N-dialkylamino (in which the alkyl groups can also be substituted), esters (-C(O)-OR, where R is groups such as alkyl, aryl, etc.,

which can be substituted), aryl (most preferred is phenyl, which can be substituted) and arylalkyl (which can be substituted).

[0050] Tie-2 (TEK) is a member of a recently discovered family of endothelial cell specific receptor tyrosine kinases which is involved in critical angiogenic processes, such as vessel branching, sprouting, remodeling, maturation and stability. Tie-2 is the first mammalian receptor tyrosine kinase for which both agonist ligand(s) (e.g., Angiopoietin1 ("Ang1"), which stimulates receptor autophosphorylation and signal transduction), and antagonist ligand(s) (e.g., Angiopoietin2 ("Ang2")), have been identified. Knock-out and transgenic manipulation of the expression of Tie-2 and its ligands indicates tight spatial and temporal control of Tie-2 signaling is essential for the proper development of new vasculature. The current model suggests that stimulation of Tie-2 kinase by the Ang1 ligand is directly involved in the branching, sprouting and outgrowth of new vessels, and recruitment and interaction of periendothelial support cells important in maintaining vessel integrity and inducing quiescence. The absence of Ang1 stimulation of Tie-2 or the inhibition of Tie-2 autophosphorylation by Ang2, which is produced at high levels at sites of vascular regression, may cause a loss in vascular structure and matrix contacts resulting in endothelial cell death, especially in the absence of growth/survival stimuli. The situation is however more complex, since at least two additional Tie-2 ligands (Ang3 and Ang4) have recently been reported, and the capacity for heterooligomerization of the various agonistic and antagonistic angiopoietins, thereby modifying their activity, has been demonstrated. Targeting Tie-2 ligand-receptor interactions as an antiangiogenic therapeutic approach is thus less favored and a kinase inhibitory strategy preferred.

[0051] The soluble extracellular domain of Tie-2 ("Ex-Tek") can act to disrupt the establishment of tumor vasculature in a breast tumor xenograft and lung metastasis models and in tumor-cell mediated ocular neovascularization. By adenoviral infection, the *in vivo* production of mg/ml levels ExTek in rodents may be achieved for 7-10 days with no adverse side effects. These results suggest that disruption of Tie-2 signaling pathways in normal healthy animals may be well tolerated. These Tie-2 inhibitory responses to ExTek may be a consequence sequestration of ligand(s) and/or generation of a nonproductive heterodimer with full-length Tie-2.

[0052] The compounds of this invention have inhibitory activity against protein kinases. That is, these compounds modulate signal transduction by protein kinases. Compounds of this invention inhibit protein kinases from serine/threonine and tyrosine kinase classes. In particular, these compounds selectively inhibit the activity of the KDR/FLK-1/VEGFR-2 tyrosine kinases. Certain compounds of this invention also inhibit the activity of additional tyrosine kinases such as Flt-1/VEGFR-1, Flt-4/VEGFR-3, Tie-1, Tie-2, FGFR, PDGFR, IGF-1R, c-Met, Src-subfamily kinases such as Lck, hck, fgr, Src,

fyn, yes, etc. Additionally, some compounds of this invention significantly inhibit serine/threonine kinases such as PKC, MAP kinases, erk, CDKs, Plk-1, or Raf-1 which play an essential role in cell proliferation and cell-cycle progression. The potency and specificity of the generic compounds of this invention towards a particular protein kinase can often be altered and optimized by variations in the nature, number and arrangement of the substituents (i.e., R₁, R₂, R₃, A and ring 1) and conformational restrictions. In addition the metabolites of certain compounds may also possess significant protein kinase inhibitory activity.

[0053] The compounds of this invention, act, it is believed, by inhibiting the activity of KDR tyrosine kinase which is involved in the process of vascular hyperpermeability and edema formation. The KDR tyrosine kinase may also be referred to as FLK-1 tyrosine kinase, NYK tyrosine kinase or VEGFR-2 tyrosine kinase. KDR tyrosine kinase is activated when vascular endothelial cell growth factor (VEGF) or another activating ligand (such as VEGF-C, VEGF-D, VEGF-E or HIV Tat protein) binds to a KDR tyrosine kinase receptor which lies on the surface of vascular endothelial cells. Following such KDR tyrosine kinase activation, hyperpermeability of the blood vessels occurs and fluid moves from the blood stream past the blood vessel walls into the interstitial spaces, thereby forming an area of edema. Diapedesis also often accompanies this response. Similarly, excessive vascular hyperpermeability can disrupt normal molecular exchange across the endothelium in critical tissues and organs (e.g., lung and kidney), thereby causing macromolecular extravasation and deposition. Following this acute response to KDR stimulation which is believed to facilitate the subsequent angiogenic process, prolonged KDR tyrosine kinase stimulation results in the proliferation and chemotaxis of vascular endothelial cells and formation of new vessels. By inhibiting KDR tyrosine kinase activity, either by blocking the production of the activating ligand, by blocking the activating ligand binding to the KDR tyrosine kinase receptor, by preventing receptor dimerization and transphosphorylation, by inhibiting the enzyme activity of the KDR tyrosine kinase (inhibiting the phosphorylation function of the enzyme) or by some other mechanism that interrupts its downstream signaling (D. Mukhopedhyay et al., Cancer Res. 58:1278-1284 (1998) and references therein), hyperpermeability, as well as associated extravasation, subsequent edema formation and matrix deposition, and angiogenic responses, may be inhibited and minimized.

[0054] One group of preferred compounds of this invention have the property of inhibiting KDR tyrosine kinase activity without significantly inhibiting Flt-1 tyrosine kinase activity (Flt-1 tyrosine kinase is also referred to as VEGFR-1 tyrosine kinase). Both KDR tyrosine kinase and Flt-1 tyrosine kinase are activated by VEGF binding to KDR tyrosine kinase receptors and to Flt-1 tyrosine kinase receptors, respectively. Certain preferred compounds of this invention are unique because they inhibit

the activity of one VEGF-receptor tyrosine kinase (KDR) that is activated by activating ligands but do not inhibit other receptor tyrosine kinases, such as Flt-1, that are also activated by certain activating ligands. In this manner, certain preferred compounds of this invention are, therefore, selective in their tyrosine kinase inhibitory activity.

[0055] In one embodiment, the present invention provides a method of treating a protein kinase-mediated condition in a patient, comprising administering to the patient a therapeutically or prophylactically effective amount of one or more compounds of Formula I.

[0056] A "protein kinase-mediated condition" or a "condition mediated by protein kinase activity" is a medical condition, such as a disease or other undesirable physical condition, the genesis or progression of which depends, at least in part, on the activity of at least one protein kinase. The protein kinase can be, for example, a protein tyrosine kinase or a protein serine/threonine kinase.

[0057] A "therapeutically effective amount" is an amount of a compound of Formula I or a combination of two or more such compounds, which inhibits, totally or partially, the progression of the condition or alleviates, at least partially, one or more symptoms of the condition. A therapeutically effective amount can also be an amount which is prophylactically effective. The amount which is therapeutically effective will depend upon the patient's size and gender, the condition to be treated, the severity of the condition and the result sought. For a given patient, a therapeutically effective amount can be determined by methods known to those of skill in the art.

[0058] The Src, Tec, Jak, Map, Csk, NFκB and Syk families of kinases play pivotal roles in the regulation of immune function. The Src family currently includes Fyn, Lck, Fgr, Fes, Lyn, Src, Yrk, Fyk, Yes, Hck, and Blk. The Syk family is currently understood to include only Zap and Syk. The TEC family includes Tec, Btk, Rlk and Itk. The Janus family of kinases is involved in the transduction of growth factor and proinflammatory cytokine signals through a number of receptors. Although BTK and ITK, members of the Tec family of kinases, play a less well understood role in immunobiology, their modulation by an inhibitor may prove therapeutically beneficial. The Csk family is currently understood to include Csk and Chk. The kinases RIP, IRAK-1, IRAK-2, NIK, p38 MAP kinases, Jnk, IKK-1 and IKK-2 are involved in the signal transduction pathways for key pro-inflammatory cytokines, such as TNF and IL-1.

[0059] A number of protein kinases have been demonstrated to be protooncogenes. Chromosome breakage (at the Itk kinase break point on chromosome 5), translocation as in the case of the Abl gene with BCR (Philadelphia chromosome), truncation in instances such as c-Kit or EGFR, or mutation (e.g., Met) result in the creation of dysregulated proteins converting them from protooncogene to oncogene products. In other tumors, oncogenesis is driven by an autocrine or paracrine ligand/growth

factor receptor interactions. Members of the src-family kinases are typically involved in downstream signal transduction thereby potentiating the oncogenesis and themselves may become oncogenic by over-expression or mutation. By inhibiting the protein kinase activity of these proteins the disease process may be disrupted. Vascular restenosis may involve FGF and/or PDGF - promoted smooth muscle and endothelial cell proliferation. The ligand stimulation of FGFR, PDGFR, IGF1-R and c-Met *in vivo* is proangiogenic, and potentiates angiogenesis dependent disorders. Inhibition of FGFR, PDGFR, c-Met, or IGF1-R kinase activities individually or in combination may be an efficacious strategy for inhibiting these phenomena,

[0060] Vascular destabilization of the antagonist ligand of Tie-2 (Ang2) is believed to induce an unstable "plastic" state in the endothelium. In the presence of high VEGF levels a robust angiogenic response may result; however, in the absence of VEGF or a VEGF-related stimulus, frank vessel regression and endothelial apoptosis can occur (Genes and Devel. 13: 1055-1066 (1999)). In an analogous manner a Tie-2 kinase inhibitor can be proangiogenic or antiangiogenic in the presence or absence of a VEGF-related stimulus, respectively.

[0061] In another aspect the present invention provides compounds of formula I as defined initially above for use as medicaments, particularly as inhibitors of protein kinase activity for example tyrosine kinase activity, serine kinase activity and threonine kinase activity. In yet another aspect the present invention provides the use of compounds of formula I as defined initially above in the manufacture of a medicament for use in the inhibition of protein kinase activity.

[0062] In this invention, the following definitions are applicable:

[0063] "Physiologically acceptable salts" refers to those salts which retain the biological effectiveness and properties of the free bases and which are obtained by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid or organic acids such as sulfonic acid, carboxylic acid, organic phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, lactic acid, tartaric acid and the like.

Pharmaceutical Formulations

[0064] The compounds of this invention can be administered to a human patient by themselves or in pharmaceutical compositions where they are mixed with suitable carriers or excipient(s) at doses to treat or ameliorate vascular hyperpermeability, edema and associated disorders. Mixtures of these compounds can also be administered to the patient as a simple mixture or in suitable formulated pharmaceutical compositions. A therapeutically effective dose further refers to that amount of the compound or compounds sufficient to result in the prevention or attenuation of inappropriate neovasculariza-

tion, progression of hyperproliferative disorders, edema, VEGF-associated hyperpermeability and/or VEGF-related hypotension. Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition.

Routes of Administration

[0065] Suitable routes of administration may, for example, include oral, eyedrop, rectal, transmucosal, topical, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections.

[0066] Alternatively, one may administer the compound in a local rather than a systemic manner, for example, via injection of the compound directly into an edematous site, often in a depot or sustained release formulation.

[0067] Furthermore, one may administer the drug in a targeted drug delivery system, for example, in a liposome coated with endothelial cell-specific antibody.

Composition/Formulation

[0068] The pharmaceutical compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes.

[0069] Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.

[0070] For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

[0071] For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained by combining the active compound with a solid excipient, optionally grinding a resulting mixture, and processing

the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

[0072] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

[0073] Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.

[0074] For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

[0075] For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

[0076] The compounds can be formulated for parenteral administration by injection, e.g. bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g. in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

[0077] Pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

[0078] Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

[0079] The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

[0080] In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly or by intramuscular injection). Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

[0081] An example of a pharmaceutical carrier for the hydrophobic compounds of the invention is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. The cosolvent system may be the VPD co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol. The VPD co-solvent system (VPD:5W) consists of VPD diluted 1:1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g. polyvinyl pyrrolidone; and other sugars or polysaccharides may substitute for dextrose.

[0082] Alternatively, other delivery systems for hydrophobic pharmaceutical compounds may be employed. Liposomes and emulsions are well known examples of delivery vehicles or carriers for hydrophobic drugs. Certain organic solvents such as dimethylsulfoxide also may

be employed, although usually at the cost of greater toxicity. Additionally, the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent. Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.

[0083] The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.

[0084] Many of the compounds of the invention may be provided as salts with pharmaceutically compatible counterions. Pharmaceutically compatible salts may be formed with many acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc. Salts tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.

Effective Dosage

[0085] Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended purpose. More specifically, a therapeutically effective amount means an amount effective to prevent development of or to alleviate the existing symptoms of the subject being treated. Determination of the effective amounts is well within the capability of those skilled in the art.

[0086] For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cellular assays. For example, a dose can be formulated in cellular and animal models to achieve a circulating concentration range that includes the IC_{50} as determined in cellular assays (i.e., the concentration of the test compound which achieves a half-maximal inhibition of a given protein kinase activity). In some cases it is appropriate to determine the IC_{50} in the presence of 3 to 5% serum albumin since such a determination approximates the binding effects of plasma protein on the compound. Such information can be used to more accurately determine useful doses in humans. Further, the most preferred compounds for systemic administration effectively inhibit protein kinase signaling in intact cells at levels that are safely achievable in plasma.

[0087] A therapeutically effective dose refers to that amount of the compound that results in amelioration of symptoms in a patient. Toxicity and therapeutic efficacy of such compounds can be determined by standard phar-

maceutical procedures in cell cultures or experimental animals, e.g., for determining the maximum tolerated dose (MTD) and the ED₅₀ (effective dose for 50% maximal response). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between MTD and ED₅₀. Compounds which exhibit high therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED₅₀ with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g. Fingl *et al.*, 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 pl). In the treatment of crises, the administration of an acute bolus or an infusion approaching the MTD may be required to obtain a rapid response.

[0088] Dosage amount and interval may be adjusted individually to provide plasma levels of the active moiety which are sufficient to maintain the kinase modulating effects, or minimal effective concentration (MEC). The MEC will vary for each compound but can be estimated from *in vitro* data; e.g. the concentration necessary to achieve 50-90% inhibition of protein kinase using the assays described herein. Dosages necessary to achieve the MEC will depend on individual characteristics and route of administration. However, HPLC assays or bioassays can be used to determine plasma concentrations.

[0089] Dosage intervals can also be determined using the MEC value. Compounds should be administered using a regimen which maintains plasma levels above the MEC for 10-90% of the time, preferably between 30-90% and most preferably between 50-90% until the desired amelioration of symptoms is achieved. In cases of local administration or selective uptake, the effective local concentration of the drug may not be related to plasma concentration.

[0090] The amount of composition administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.

Packaging

[0091] The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. Compositions comprising a compound of the invention formulated in a compatible pharmaceutical carrier may also be prepared, placed in an appropriate container, and labeled

for treatment of an indicated condition.

[0092] In some formulations it may be beneficial to use the compounds of the present invention in the form of particles of very small size, for example as obtained by fluid energy milling.

[0093] The use of compounds of the present invention in the manufacture of pharmaceutical compositions is illustrated by the following description. In this description the term "active compound" denotes any compound of the invention but particularly any compound which is the final product of one of the preceding Examples.

a) Capsules

[0094] In the preparation of capsules, 10 parts by weight of active compound and 240 parts by weight of lactose can be de-aggregated and blended. The mixture can be filled into hard gelatin capsules, each capsule containing a unit dose or part of a unit dose of active compound.

b) Tablets

[0095] Tablets can be prepared from the following ingredients.

Parts by weight	
Active compound	10
Lactose	190
Maize starch	22
Polyvinylpyrrolidone	10
Magnesium stearate	3

[0096] The active compound, the lactose and some of the starch can be de-aggregated, blended and the resulting mixture can be granulated with a solution of the polyvinyl- pyrrolidone in ethanol. The dry granulate can be blended with the magnesium stearate and the rest of the starch. The mixture is then compressed in a tableting machine to give tablets each containing a unit dose or a part of a unit dose of active compound.

c) Enteric coated tablets

[0097] Tablets can be prepared by the method described in (b) above. The tablets can be enteric coated in a conventional manner using a solution of 20% cellulose acetate phthalate and 3% diethyl phthalate in ethanol:dichloromethane (1:1).

d) Suppositories

[0098] In the preparation of suppositories, 100 parts by weight of active compound can be incorporated in 1300 parts by weight of triglyceride suppository base and the mixture formed into suppositories each containing a therapeutically effective amount of active ingredient.

[0099] In the compositions of the present invention the active compound may, if desired, be associated with other compatible pharmacologically active ingredients. For example, the compounds of this invention can be administered in combination with one or more additional pharmaceutical agents that inhibit or prevent the production of VEGF or angiopoietins, attenuate intracellular responses to VEGF or angiopoietins, block intracellular signal transduction, inhibit vascular hyperpermeability, reduce inflammation, or inhibit or prevent the formation of edema or neovascularization. The compounds of the invention can be administered prior to, subsequent to or simultaneously with the additional pharmaceutical agent, whichever course of administration is appropriate. The additional pharmaceutical agents include but are not limited to anti-edemic steroids, NSAIDS, ras inhibitors, anti-TNF agents, anti-IL1 agents, antihistamines, PAF-antagonists, COX-1 inhibitors, COX-2 inhibitors, NO synthase inhibitors, Akt/PTB inhibitors, IGF-1R inhibitors, PKC inhibitors and PI3 kinase inhibitors. The compounds of the invention and the additional pharmaceutical agents act either additively or synergistically.

[0100] The present invention also comprises the use of a compound of formula I as a medicament.

[0101] The *in vitro* potency of compounds in inhibiting these protein kinases may be determined by the procedures detailed below.

[0102] The potency of compounds can be determined by the amount of inhibition of the phosphorylation of an exogenous substrate (e.g., synthetic peptide (Z. Songyang et al., Nature. 373:536-539) by a test compound relative to control.

KDR Tyrosine Kinase Production Using Baculovirus System:

[0103] The coding sequence for the human KDR intracellular domain (aa789-1354) was generated through PCR using cDNAs isolated from HUVEC cells. A poly-His6 sequence was introduced at the N-terminus of this protein as well. This fragment was cloned into transfection vector pVL1393 at the Xba 1 and Not 1 site. Recombinant baculovirus (BV) was generated through co-transfection using the BaculoGold Transfection reagent (PharMingen). Recombinant BV was plaque purified and verified through Western analysis. For protein production, SF-9 cells were grown in SF-900-II medium at 2 x 10⁶/ml, and were infected at 0.5 plaque forming units per cell (MOI). Cells were harvested at 48 hours post infection.

Purification of KDR

[0104] SF-9 cells expressing (His)₆KDR(aa789-1354) were lysed by adding 50 ml of Triton X-100 lysis buffer (20 mM Tris, pH 8.0, 137 mM NaCl, 10% glycerol, 1% Triton X-100, 1mM PMSF, 10μg/ml aprotinin, 1 μg/ml leupeptin) to the cell pellet from 1L of cell culture. The

lysate was centrifuged at 19,000 rpm in a Sorval SS-34 rotor for 30 min at 4°C. The cell lysate was applied to a 5 ml NiCl₂ chelating sepharose column, equilibrated with 50 mM HEPES, pH7.5, 0.3 M NaCl. KDR was eluted using the same buffer containing 0.25 M imidazole. Column fractions were analyzed using SDS-PAGE and an ELISA assay (below) which measures kinase activity. The purified KDR was exchanged into 25mM HEPES, pH7.5, 25mM NaCl, 5 mM DTT buffer and stored at -80°C.

Human Tie-2 Kinase Production and Purification

[0105] The coding sequence for the human Tie-2 intracellular domain (aa775-1124) was generated through PCR using cDNAs isolated from human placenta as a template. A poly-His₆ sequence was introduced at the N-terminus and this construct was cloned into transfection vector pVL 1939 at the Xba 1 and Not 1 site. Recombinant BV was generated through co-transfection using the BaculoGold Transfection reagent (PharMingen). Recombinant BV was plaque purified and verified through Western analysis. For protein production, SF-9 insect cells were grown in SF-900-II medium at 2 x 10⁶/ml, and were infected at MOI of 0.5. Purification of the His-tagged kinase used in screening was analogous to that described for KDR

Human Flt-1 Tyrosine Kinase Production and Purification

[0106] The baculoviral expression vector pVL1393 (PharMingen, Los Angeles, CA) was used. A nucleotide sequence encoding poly-His6 was placed 5' to the nucleotide region encoding the entire intracellular kinase domain of human Flt-1 (amino acids 786-1338). The nucleotide sequence encoding the kinase domain was generated through PCR using cDNA libraries isolated from HUVEC cells. The histidine residues enabled affinity purification of the protein as a manner analogous to that for KDR and ZAP70. SF-9 insect cells were infected at a 0.5 multiplicity and harvested 48 hours post infection.

EGFR Tyrosine Kinase Source

[0107] EGFR was purchased from Sigma (Cat # E-3641; 500 units/50 μl) and the EGF ligand was acquired from Oncogene Research Products/Calbiochem (Cat # PF011-100).

Expression of ZAP70

[0108] The baculoviral expression vector used was pVL1393. (PharMingen, Los Angeles, Ca.) The nucleotide sequence encoding amino acids M(H)₆ LVPP₉S was placed 5' to the region encoding the entirety of ZAP70 (amino acids 1-619). The nucleotide sequence encoding the ZAP70 coding region was generated through PCR using cDNA libraries isolated from Jurkat

immortalized T-cells. The histidine residues enabled affinity purification of the protein (vide infra). The LVPR₉S bridge constitutes a recognition sequence for proteolytic cleavage by thrombin, enabling removal of the affinity tag from the enzyme. SF-9 insect cells were infected at a multiplicity of infection of 0.5 and harvested 48 hours post infection.

Extraction and purification of ZAP70

[0109] SF-9 cells were lysed in a buffer consisting of 20 mM Tris, pH 8.0, 137 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM PMSF, 1 µg/ml leupeptin, 10 µg/ml aprotinin and 1 mM sodium orthovanadate. The soluble lysate was applied to a chelating sepharose HiTrap column (Pharmacia) equilibrated in 50 mM HEPES, pH 7.5, 0.3 M NaCl. Fusion protein was eluted with 250 mM imidazole. The enzyme was stored in buffer containing 50 mM HEPES, pH 7.5, 50 mM NaCl and 5 mM DTT.

Protein kinase source

[0110] Lck, Fyn, Src, Blk, Csk, and Lyn, and truncated forms thereof may be commercially obtained (e.g. from Upstate Biotechnology Inc. (Saranac Lake, N.Y) and Santa Cruz Biotechnology Inc. (Santa Cruz, Ca.)) or purified from known natural or recombinant sources using conventional methods. Enzyme Linked Immunosorbent Assay (ELISA) For PTKs

[0111] Enzyme linked immunosorbent assays (ELISA) were used to detect and measure the presence of tyrosine kinase activity. The ELISA were conducted according to known protocols which are described in, for example, Voller, et al., 1980, "Enzyme-Linked Immunosorbent Assay," In: Manual of Clinical Immunology, 2d ed., edited by Rose and Friedman, pp 359-371 Am. Soc. of Microbiology, Washington, D.C.

[0112] The disclosed protocol was adapted for determining activity with respect to a specific PTK. For example, preferred protocols for conducting the ELISA experiments is provided below. Adaptation of these protocols for determining a compound's activity for other members of the receptor PTK family, as well as non-receptor tyrosine kinases, are well within the abilities of those in the art. For purposes of determining inhibitor selectivity, a universal PTK substrate (e.g., random copolymer of poly (Glu₄ Tyr), 20,000-50,000 MW) was employed together with ATP (typically 5 µM) at concentrations approximately twice the apparent K_m in the assay.

[0113] The following procedure was used to assay the inhibitory effect of compounds of this invention on KDR, Flt-1, Flt-4, Tie-1, Tie-2, EGFR, FGFR, PDGFR, IGF-1-R, c-Met, Lck, hck, Blk, Csk, Src, Lyn, fgr, Fyn and ZAP70 tyrosine kinase activity:

Buffers and Solutions:

PGTPoly (Glu,Tyr) 4:1

Store powder at -20°C. Dissolve powder in phosphate buffered saline (PBS) for 50mg/ml solution. Store 1ml aliquots at -20°C. When making plates dilute to 250µg/ml in Gibco PBS.

Reaction Buffer: 100mM Hepes, 20mM MgCl₂, 4mM MnCl₂, 5mM DTT, 0.02%BSA, 200µM NaVO₄, pH 7.10

ATP: Store aliquots of 100mM at -20°C. Dilute to 20µM in water

Washing Buffer: PBS with 0.1% Tween 20

Antibody Diluting Buffer: 0.1 % bovine serum albumin (BSA) in PBS TMB Substrate: mix TMB substrate and Peroxide solutions 9:1 just before use or use K-Blue Substrate from Neogen

Stop Solution: 1M Phosphoric Acid

Procedure

1. Plate Preparation:

[0114] Dilute PGT stock (50mg/ml, frozen) in PBS to a 250µg/ml. Add 125µl per well of Corning modified flat bottom high affinity ELISA plates (Coming #25805-96). Add 125µl PBS to blank wells. Cover with sealing tape and incubate overnight 37°C. Wash 1x with 250µl washing buffer and dry for about 2hrs in 37°C dry incubator. Store coated plates in sealed bag at 4°C until used.

2. Tyrosine Kinase Reaction:

[0115]

- Prepare inhibitor solutions at a 4x concentration in 20% DMSO in water.
- Prepare reaction buffer
- Prepare enzyme solution so that desired units are in 50µl, e.g. for KDR make to 1 ng/µl for a total of 50ng per well in the reactions. Store on ice.
- Make 4x ATP solution to 20µM from 100mM stock in water. Store on ice
- Add 50µl of the enzyme solution per well (typically 5-50 ng enzyme/well depending on the specific activity of the kinase)
- Add 25µl 4x inhibitor
- Add 25µl 4x ATP for inhibitor assay
- Incubate for 10 minutes at room temperature
- Stop reaction by adding 50µl 0.05N HCl per well
- Wash plate

* *Final Concentrations for Reaction: 5µM ATP, 5% DMSO

3. Antibody Binding

[0116]

- Dilute 1mg/ml aliquot of PY20-HRP (Pierce) antibody(a phosphotyrosine antibody)to 50ng/ml in

0.1% BSA in PBS by a 2 step dilution (100x, then 200x)

- Add 100 μ l Ab per well. Incubate 1 hr at room temp. Incubate 1hr at 4C.
- Wash 4x plate

4. Color reaction

[0117]

- Prepare TMB substrate and add 100 μ l per well
- Monitor OD at 650nm until 0.6 is reached
- Stop with 1M Phosphoric acid. Shake on plate reader.
- Read OD immediately at 450nm

[0118] Optimal incubation times and enzyme reaction conditions vary slightly with enzyme preparations and are determined empirically for each lot.

[0119] For Lck, the Reaction Buffer utilized was 100 mM MOPSO, pH 6.5, 4 mM MnCl₂, 20 mM MgCl₂, 5 mM DTT, 0.2% BSA, 200 mM NaVO₄ under the analogous assay conditions.

[0120] Compounds of formulas 1-109 may have therapeutic utility in the treatment of diseases involving both identified, including those not mentioned herein, and as yet unidentified protein tyrosine kinases which are inhibited by compounds of formulas 1-109.

Cdc2 source

[0121] The human recombinant enzyme and assay buffer may be obtained commercially (New England Biolabs, Beverly, MA. USA) or purified from known natural or recombinant sources using conventional methods.

Cdc2 Assay

[0122] A protocol that can be used is that provided with the purchased reagents with minor modifications. In brief, the reaction is carried out in a buffer consisting of 50mM Tris pH 7.5, 100mM NaCl, 1mM EGTA, 2mM DTT, 0.01 % Brij, 5% DMSO and 10mM MgCl₂ (commercial buffer) supplemented with fresh 300 μ M ATP (31 μ Ci/ml) and 30 μ g/ml histone type IIIss final concentrations. A reaction volume of 80 μ L, containing units of enzyme, is run for 20 minutes at 25 degrees C in the presence or absence of inhibitor. The reaction is terminated by the addition of 120 μ L of 10% acetic acid. The substrate is separated from unincorporated label by spotting the mixture on phosphocellulose paper, followed by 3 washes of 5 minutes each with 75mM phosphoric acid. Counts are measured by a betacounter in the presence of liquid scintillant.

PKC kinase source

[0123] The catalytic subunit of PKC may be obtained

commercially (Calbiochem).

PKC kinase assay

[0124] A radioactive kinase assay is employed following a published procedure (Yasuda, I., Kirshimoto, A., Tanaka, S., Tominaga, M., Sakurai, A., Nishizuka, Y. Biochemical and Biophysical Research Communication 3: 166, 1220-1227 (1990)). Briefly, all reactions are performed in a kinase buffer consisting of 50 mM Tris-HCl pH7.5, 10mM MgCl₂, 2mM DTT, 1mM EGTA, 100 μ M ATP, 8 μ M peptide, 5% DMSO and ³³P ATP (8Ci/mM). Compound and enzyme are mixed in the reaction vessel and the reaction is initiated by addition of the ATP and substrate mixture. Following termination of the reaction by the addition of 10 μ L stop buffer (5 mM ATP in 75mM phosphoric acid), a portion of the mixture is spotted on phosphocellulose filters. The spotted samples are washed 3 times in 75 mM phosphoric acid at room temperature for 5 to 15 minutes. Incorporation of radiolabel is quantified by liquid scintillation counting.

Erk2 enzyme source

[0125] The recombinant murine enzyme and assay buffer may be obtained commercially (New England Biolabs, Beverly MA. USA) or purified from known natural or recombinant sources using conventional methods.

Erk2 enzyme assay

[0126] In brief, the reaction is carried out in a buffer consisting of 50 mM Tris pH 7.5, 1mM EGTA, 2mM DTT, 0.01% Brij, 5% DMSO and 10 mM MgCl₂ (commercial buffer) supplemented with fresh 100 μ M ATP (31 μ Ci/ml) and 30 μ M myelin basic protein under conditions recommended by the supplier. Reaction volumes and method of assaying incorporated radioactivity are as described for the PKC assay (*vide supra*).

In Vitro Models for T-cell Activation

[0127] Upon activation by mitogen or antigen, T-cells are induced to secrete IL-2, a growth factor that supports their subsequent proliferative phase. Therefore, one may measure either production of IL-2 from or cell proliferation of, primary T-cells or appropriate T-cell lines as a surrogate for T-cell activation. Both of these assays are well described in the literature and their parameters well documented (in Current Protocols in Immunology, Vol 2, 7.10.1-7.11.2).

[0128] In brief, T-cells may be activated by co-culture with allogenic stimulator cells, a process termed the one-way mixed lymphocyte reaction. Responder and stimulator peripheral blood mononuclear cells are purified by Ficoll-Hypaque gradient (Pharmacia) per directions of the manufacturer. Stimulator cells are mitotically inactivated by treatment with mitomycin C (Sigma) or

gamma irradiation. Responder and stimulator cells are co-cultured at a ratio of two to one in the presence or absence of the test compound. Typically 10^5 responders are mixed with 5×10^4 stimulators and plated (200 μ l volume) in a U bottom microtiter plate (Costar Scientific). The cells are cultured in RPMI 1640 supplemented with either heat inactivated fetal bovine serum (Hyclone Laboratories) or pooled human AB serum from male donors, 5×10^{-5} M 2mercaptoethanol and 0.5% DMSO. The cultures are pulsed with 0.5 μ Ci of 3 H thymidine (Amersham) one day prior to harvest (typically day three). The cultures are harvested (Betaplate harvester, Wallac) and isotope uptake assessed by liquid scintillation (Betaplate, Wallac).

[0129] The same culture system may be used for assessing T-cell activation by measurement of IL-2 production. Eighteen to twenty-four hours after culture initiation, the supernatants are removed and the IL-2 concentration is measured by ELISA (R and D Systems) following the directions of the manufacturer.

In-vivo Models of T-Cell Activation

[0130] The *in vivo* efficacy of compounds can be tested in animal models known to directly measure T-cell activation or for which T-cells have been proven the effectors. T-cells can be activated *in vivo* by ligation of the constant portion of the T-cell receptor with a monoclonal anti-CD3 antibody (Ab). In this model, BALB/c mice are given 10 μ g of anti-CD3 Ab intraperitoneally two hours prior to exsanguination. Animals to receive a test drug are pre-treated with a single dose of the compound one hour prior to anti-CD3 Ab administration. Serum levels of the proinflammatory cytokines interferon- γ (IFN- γ) and tumor necrosis factor- α (TNF- α), indicators of T-cell activation, are measured by ELISA. A similar model employs *in vivo* T-cell priming with a specific antigen such as keyhole limpet hemocyanin (KLH) followed by a secondary *in vitro* challenge of draining lymph node cells with the same antigen. As previously, measurement of cytokine production is used to assess the activation state of the cultured cells. Briefly, C57BL/6 mice are immunized subcutaneously with 100 μ g KLH emulsified in complete Freund's adjuvant (CFA) on day zero. Animals are pre-treated with the compound one day prior to immunization and subsequently on days one, two and three post immunization. Draining lymph nodes are harvested on day 4 and their cells cultured at 6×10^6 per ml in tissue culture medium (RPMI 1640 supplemented with heat inactivated fetal bovine serum (Hyclone Laboratories) 5×10^{-5} M 2-mercaptoethanol and 0.5% DMSO) for both twenty-four and forty-eight hours. Culture supernatants are then assessed for the autocrine T-cell growth factor Interleukin-2 (IL-2) and/or IFN- γ levels by ELISA.

[0131] Lead compounds can also be tested in animal models of human disease. These are exemplified by experimental auto-immune encephalomyelitis (EAE) and collagen-induced arthritis (CIA). EAE models which mim-

ic aspects of human multiple sclerosis have been described in both rats and mice (reviewed FASEB J. 5: 2560-2566, 1991; murine model: Lab. Invest. 4(3):278, 1981; rodent model: J. Immunol. 146(4):1163-8, 1991). Briefly, mice or rats are immunized with an emulsion of myelin basic protein (MBP), or neurogenic peptide derivatives thereof, and CFA. Acute disease can be induced with the addition of bacterial toxins such as *bordetella pertussis*. Relapsing/remitting disease is induced by adoptive transfer of T-cells from MBP/ peptide immunized animals.

[0132] CIA may be induced in DBA/1 mice by immunization with type II collagen (J. Immunol. 142(7): 2237-2243). Mice will develop signs of arthritis as early as ten days following antigen challenge and may be scored for as long as ninety days after immunization. In both the EAE and CIA models, a compound may be administered either prophylactically or at the time of disease onset. Efficacious drugs should reduce severity and/or incidence.

[0133] Certain compounds of this invention which inhibit one or more angiogenic receptor PTK, and/or a protein kinase such as Ick involved in mediating inflammatory responses can reduce the severity and incidence of arthritis in these models.

[0134] Compounds can also be tested in mouse allograft models, either skin (reviewed in Ann. Rev. Immunol., 10:333-58, 1992; Transplantation: 57(12): 1701-1706, 1994) or heart (Am. J. Anat.: 113:273, 1963). Briefly, full thickness skin grafts are transplanted from C57BL/6 mice to BALB/c mice. The grafts can be examined daily, beginning at day six, for evidence of rejection. In the mouse neonatal heart transplant model, neonatal hearts are ectopically transplanted from C57BL/6 mice into the ear pinnae of adult CBA/J mice. Hearts start to beat four to seven days post transplantation and rejection may be assessed visually using a dissecting microscope to look for cessation of beating.

Cellular Receptor PTK Assays

[0135] The following cellular assay was used to determine the level of activity and effect of the different compounds of the present invention on KDR/VEGFR2. Similar receptor PTK assays employing a specific ligand stimulus can be designed along the same lines for other tyrosine kinases using techniques well known in the art.

[0136] VEGF-Induced KDR Phosphorylation in Human Umbilical Vein Endothelial Cells (HUVEC) as Measured by Western Blots:

1. HUVEC cells (from pooled donors) can be purchased from Clonetics (San Diego, CA) and cultured according to the manufacturer directions. Only early passages (3-8) are used for this assay. Cells are cultured in 100 mm dishes (Falcon for tissue culture; Becton Dickinson; Plymouth, England) using complete EBM media (Clonetics).

2. For evaluating a compound's inhibitory activity, cells are trypsinized and seeded at $0.5-1.0 \times 10^5$ cells/well in each well of 6-well cluster plates (Costar; Cambridge, MA).

3. 3-4 days after seeding, plates are typically 90-100% confluent. Medium is removed from all the wells, cells are rinsed with 5-10ml of PBS and incubated 18-24h with 5ml of EBM base media with no supplements added (i.e., serum starvation).

4. Serial dilutions of inhibitors are added in 1ml of EBM media (25 μ M, 5 μ M, or 1 μ M final concentration to cells and incubated for one hour at 37 C. Human recombinant VEGF₁₆₅ (R & D Systems) is then added to all the wells in 2 ml of EBM medium at a final concentration of 50ng/ml and incubated at 37 C for 10 minutes. Control cells untreated or treated with VEGF only are used to assess background phosphorylation and phosphorylation induction by VEGF.

[0137] All wells are then rinsed with 5-10ml of cold PBS containing 1mM Sodium Orthovanadate (Sigma) and cells are lysed and scraped in 200 μ l of RIPA buffer (50mM Tris-HCl) pH7, 150mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, 1mM EDTA) containing protease inhibitors (PMSF 1mM, aprotinin 1 μ g/ml, pepstatin 1 μ g/ml, leupeptin 1 μ g/ml, Na vanadate 1mM, Na fluoride 1mM) and 1 μ g/ml of Dnase (all chemicals from Sigma Chemical Company, St Louis, MO). The lysate is spun at 14,000 rpm for 30min, to eliminate nuclei.

[0138] Equal amounts of proteins are then precipitated by addition of cold (-20 C) Ethanol (2 volumes) for a minimum of 1 hour or a maximum of overnight. Pellets are reconstituted in Laemli sample buffer containing 5% -mercaptoethanol (BioRad; Hercules, CA) and boiled for 5min. The proteins are resolved by polyacrylamide gel electrophoresis (6%, 1.5mm Novex, San Deigo, CA) and transferred onto a nitrocellulose membrane using the Novex system. After blocking with bovine serum albumin (3%), the proteins are probed overnight with anti-KDR polyclonal antibody (C20, Santa Cruz Biotechnology; Santa Cruz, CA) or with anti-phosphotyrosine monoclonal antibody (4G10, Upstate Biotechnology, Lake Placid, NY) at 4 C. After washing and incubating for 1 hour with HRP-conjugated F(ab)₂ of goat anti-rabbit or goat-anti-mouse IgG the bands are visualized using the emission chemiluminescence (ECL) system (Amersham Life Sciences, Arlington Height, IL).

In vivo Uterine Edema Model

[0139] This assay measures the capacity of compounds to inhibit the acute increase in uterine weight in mice which occurs in the first few hours following estrogen stimulation. This early onset of uterine weight increase is known to be due to edema caused by increased permeability of uterine vasculature. Cullinan-Bove and Koss (Endocrinology (1993), 133:829-837) demonstrated a close temporal relationship of estrogen-stimulated

uterine edema with increased expression of VEGF mRNA in the uterus. These results have been confirmed by the use of neutralizing monoclonal antibody to VEGF which significantly reduced the acute increase in uterine weight following estrogen stimulation (WO 97/42187). Hence, this system can serve as a model for *in vivo* inhibition of VEGF signalling and the associated hyperpermeability and edema.

Materials: All hormones can be purchased from Sigma (St. Louis, MO) or Cal Biochem (La Jolla, CA) as lyophilized powders and prepared according to supplier instructions.

Vehicle components (DMSO, Cremaphor EL) can be purchased from Sigma (St Louis, MO).

Mice (Balb/c, 8-12 weeks old) can be purchased from Taconic (Germantown, NY) and housed in a pathogen-free animal facility in accordance with institutional Animal Care and Use Committee Guidelines.

Method:

Day 1: Balb/c mice are given an intraperitoneal (i.p.) injection of 12.5 units of pregnant mare's serum gonadotropin (PMSG).

Day 3: Mice receive 15 units of human chorionic gonadotropin (hCG) i.p.

Day 4: Mice are randomized and divided into groups of 5-10. Test compounds are administered by i.p., i.v. or p.o. routes depending on solubility and vehicle at doses ranging from 1-100 mg/kg. Vehicle control group receive vehicle only and two groups are left untreated.

[0140] Thirty minutes later, experimental, vehicle and 1 of the untreated groups are given an i.p. injection of 17 -estradiol (500 μ g/kg). After 2-3 hours, the animals are sacrificed by CO₂ inhalation. Following a midline incision, each uterus was isolated and removed by cutting just below the cervix and at the junctions of the uterus and oviducts. Fat and connective tissue were removed with care not to disturb the integrity of the uterus prior to weighing (wet weight). Uteri are blotted to remove fluid by pressing between two sheets of filter paper with a one liter glass bottle filled with water. Uteri are weighed following blotting (blotted weight). The difference between wet and blotted weights is taken as the fluid content of the uterus. Mean fluid content of treated groups is compared to untreated or vehicle treated groups. Significance is determined by Student's test. Non-stimulated control group is used to monitor estradiol response.

[0141] Certain compounds of this invention which are inhibitors of angiogenic receptor tyrosine kinases can also be shown active in a Matrigel implant model of neovascularization. The Matrigel neovascularization model involves the formation of new blood vessels within a clear marble of extracellular matrix implanted subcutaneously which is induced by the presence of proangiogenic factor producing tumor cells (for examples see: Passaniti, A., et al, Lab. Investig. (1992), 67(4), 519-528; Anat. Rec.

(1997), 249(1), 63-73; Int. J. Cancer (1995), 63(5), 694-701; Vasc. Biol. (1995), 15(11), 1857-6). The model preferably runs over 3-4 days and endpoints include macroscopic visual/image scoring of neovascularization, microscopic microvessel density determinations, and hemoglobin quantitation (Drabkin method) following removal of the implant versus controls from animals untreated with inhibitors. The model may alternatively employ bFGF or HGF as the stimulus.

Example 1:

7-Cyclopentyl-5-(4-phenoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine

a) 2-cyclopentylacetonitrile

[0142] A mixture of sodium hydride (2.17 g, 60% in oil, 54.2 mmol) in diethyl ether (100 mL) was cooled to 0°C then treated with diethyl(cyanomethyl) phosphonate (9.6 g, 54.2 mmol) while maintaining the temperature of the mixture at less than 0°C. Cyclopentanone (4.13 g, 49.3 mmol) in diethyl ether (25 mL) was added to the mixture at less than 5°C then the reaction was warmed to ambient temperature and stirred for an additional 16 hours. Water (240 mL) was added to the mixture and the layers were then separated. The aqueous layer was extracted with diethyl ether (50 mL). The combined organic solutions were extracted with water (50 mL) then brine (50 mL) and finally dried over magnesium sulfate, filtered and the filtrate concentrated under reduced pressure. The resulting residue was dissolved in ethanol (40 mL) then 10% palladium on carbon (250 mg) was added and the mixture hydrogenated at atmospheric pressure and ambient temperature for 16 hours. The catalyst was removed by filtration through a pad of celite and the filtrate concentrated to an oil under reduced pressure. The title compound was purified by fractional distillation to give 4.08 g (75.6%) as a light yellow oil (boiling point 63°C at 20 torr). ¹H NMR (Chloroform-*d*, 400 MHz) δ 2.35 (d, 2H), 2.18 (m, 1H), 1.87 (m, 2H), 1.59-1.69 (m, 4H), 1.29 (m, 2H).

b) 1-cyclopentyl-2-oxoethylcyanide

[0143] A mixture of 2-cyclopentylacetonitrile (0.50 g, 4.59 mmol) in tetrahydrofuran (10 mL) was cooled to -60°C then treated with 1.7 M *tert*-butyllithium in pentane (3.25 mL, 5.50 mmol) while maintaining the reaction temperature at less than -55°C. The solution was stirred for 10 minutes then ethyl formate (0.41 g, 5.50 mmol) was added dropwise. The mixture was warmed to ambient temperature and stirred an additional 16 hours. The mixture was concentrated under reduced pressure and the resulting residue applied to a silica gel column and eluted with dichloromethane/ethyl acetate (95:5). The fractions containing material with an *R_f* of 0.1-0.3 [TLC, dichloromethane/ethyl acetate (95:5), potassium permanga-

nate stain) were combined and concentrated to give an oil which was used without further purification: ¹H NMR (Chloroform-*d*, 400 MHz) δ 9.57 (s, 1H), 3.54 (d, 1H), 2.45 (m, 1H), 1.4-1.9 (m, 8H).

c) (4-phenoxyanilino)methyl cyanide

[0144] A mixture of 4-phenoxyaniline (7.0 g, 37.8 mmol), bromoacetonitrile (4.5 g, 37.8 mmol) and triethylamine (4.2 g, 41.6 mmol) in tetrahydrofuran (50 mL) was heated at 85°C for 5.25 hours then cooled and another portion of bromoacetonitrile (6.5 g, 5.46 mmol) was added. The mixture was heated at 85°C for 18 hours then cooled and concentrated under reduced pressure. The residue was partitioned between dichloromethane (50 mL) and water (50 mL). The aqueous layer was extracted with dichloromethane (30 mL) then the combined organic solutions were extracted with 5 N aqueous sodium hydroxide (30 mL), dried over magnesium sulfate, filtered and the filtrate concentrated under reduced pressure. The residue was then purified by flash chromatography on silica gel using dichloromethane/ethyl acetate (98:2) as an eluent to provide 3.8 g (45%) of the title compound as a dark brown solid: ¹H NMR (DMSO-*d*₆, 400 MHz) δ 7.32 (t, 2H), 7.03 (t, 1H), 6.87-6.94 (m, 4H), 6.76 (d, 2H), 6.26 (bs, 2H), 4.25 (s, 2H); RP-HPLC (Hypersil HS-C18, 5 μm, 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 25 min, 1 mL/min) t_r 18.4 min.; MS: MH⁺ 225.1.

d) 3-amino-4-cyclopentyl-1-(4-phenoxyphenyl)-1H-2-pyrrolicarbonitrile

[0145] A mixture of (4-phenoxyanilino)methyl cyanide (0.68 g, 3.30 mmol) and 1-cyclopentyl-2-oxoethylcyanide (0.54 g, 3.94 mmol) in 1,2-dimethoxyethane (10 mL) was treated with 2 drops of acetic acid then heated at 85°C for 45 minutes. The mixture was cooled to ambient temperature then 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) (1.13 g, 9.09 mmol) was added. The mixture was then heated at 65°C for 16 hours and 85°C for 6 hours. Fresh DBN (0.25 mL) was added and the mixture was heated at 85°C for an additional 18 hours. The solvent was removed under reduced pressure then the residue was applied to a silica gel column and eluted with heptane/ethyl acetate (7:3) to provide 185 mg (17.8%) of the title compound as a glass: ¹H NMR (DMSO-*d*₆, 400 MHz) δ 7.42 (m, 4H), 7.17 (t, 1H), 7.04-7.11 (m, 4H), 6.99 (s, 1H), 5.10 (bs, 2H), 2.82 (m, 1H), 1.97 (m, 2H), 1.69 (m, 2H), 1.58 (m, 2H); RP-HPLC (Hypersil HS-C18, 5 μm, 100A, 4.6 x 250 mm; 25%-100% acetonitrile-0.05 M ammonium acetate over 25 min, 1 mL/min) t_r 26.2 min.; MS: MH⁺ 343.9.


e) 7-cyclopentyl-5-(4-phenoxyphenyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine

[0146] A mixture of the 3-amino-4-cyclopentyl-1-(4-

phenoxyphenyl)-1*H*-2-pyrrolecarbonitrile (185 mg, 0.539 mmol) in absolute ethanol (10 mL) was treated with formamidine acetate (450 mg, 4.33 mmol) then heated at 85°C for 2 hours. The solvent was evaporated under reduced pressure then the residue was purified by preparative reverse phase HPLC to provide 145 mg (73%) of the title compound as a white solid after lyophilization: ¹H NMR (DMSO-*d*₆, 400 MHz) δ 8.19 (s, 1H), 7.44 (m, 5H), 7.19 (t, 1H), 7.13 (m, 4H), 5.79 (bs, 2H), 3.23 (m, 1H), 2.05 (m, 2H), 1.77 (m, 4H), 1.64 (m, 2H); RP-HPLC (Hypersil HS-C18, 5μm, 100A, 4.6 x 250 mm; 5%-100% acetonitrile-0.05 M ammonium acetate over 25 min, 1 mL/min) t, 23.3min.; MS: MH⁺ 371.5.


Claims

1. A compound of Formula (I), the racemic-diastereomeric mixtures, optical isomers or pharmaceutically-acceptable salts thereof,



wherein:

R₁ is



Z¹⁰⁰ is an optionally substituted phenyl,

where Z¹⁰⁰ is optionally substituted with one or more substituents each independently selected from the group consisting of F, Cl, CN, NO₂, - optionally substituted alkyl, -O-(optionally substituted alkyl), -C(O)H, -CONH₂, -NHSO₂CF₃, optionally substituted heteroaryl, COOH, -Z¹⁰⁵-C(O)N(R)₂, -Z¹⁰⁵-N(R)-C(O)-Z²⁰⁰, -Z¹⁰⁵-N(R)-S(O)₂-Z²⁰⁰, and -Z¹⁰⁵-N(R)-C(O)-N(R)-Z²⁰⁰; Z¹⁰⁵ is a covalent bond or (C₁-C₆); Z²⁰⁰ is an optionally substituted group se-

lected from group consisting of (C₁-C₆), phenyl and -(C₁-C₆), phenyl;

Z¹¹⁰ and Z¹¹¹ are each independently a covalent bond and

A is O;

R_a is hydrogen;

R₃ is H;

R₂ is -Z¹⁰¹-Z¹⁰²;

Z¹⁰¹ is a covalent bond;

Z¹⁰² is a substituted or unsubstituted cycloalkyl group.

2. A compound according to Claim 1, wherein R₂ is cyclopentyl.

3. A compound according to Claim 2, wherein

Z¹⁰⁰ is optionally substituted phenyl, where Z¹⁰⁰ is optionally substituted with one or more substituents each independently selected from the group consisting of F, COOH, NO₂, OMe, -COOMe, OCF₃ and CF₃.

4. A compound according to Claim 2, wherein

Z¹⁰⁰ is an optionally substituted phenyl, where Z¹⁰⁰ is optionally substituted with one or more substituents selected from the group consisting of alkyl, alkoxy, halo, hydroxy and alkoxycarbonyl.

5. A compound according to Claim 1, wherein R² is an optionally substituted group selected from the group consisting of cyclobutyl and cyclohexyl.

6. A compound according to Claim 5, wherein R² is optionally substituted with one or more substituents selected from the group consisting of hydroxy, alkyl, hydroxyalkyl, carboxyalkyl and phenylalkoxyalkyl.

7. A compound according to Claim 1, wherein R₁ is 4-phenoxyphenyl.

8. A compound of formula I according to claim 1 wherein R₁ = 4-phenoxyphenyl, R₂ = cyclopentyl and both R₃ = H.

9. Use of a compound of claim 1 or a physiologically acceptable salt thereof for manufacturing a medication for inhibiting one or more protein kinase activity in a patient by administration of a therapeutically effective amount to said patient.

10. The use of Claim 9 wherein said protein kinase is selected from the group consisting of KDR, FGFR-1, PDGFRβ, PDGFRα, IGF-1R, c-Met, Flt-1, Flt-4, TIE-2, TIE-1, Lck, Src, fyn, Lyn, Blk, hck, fgr and yes.


11. The use of Claim 9 wherein the protein kinase is a protein serine/threonine kinase or a protein tyrosine kinase.

12. The use of Claim 10 wherein the protein kinase is Tie-2.

13. The use of Claim 9 wherein the protein kinase activity is involved in T cell activation, B cell activation, mast cell degranulation, monocyte activation, the potentiation of an inflammatory response or a combination thereof.


Patentansprüche

1. Eine Verbindung mit der Formel (I), die racemisch-diastereomeren Mischungen, optischen Isomere oder pharmazeutisch verträglichen Salze davon,



worin:

R₁



ist;

Z¹⁰⁰ ein wahlweise substituiertes Phenyl ist,

worin Z¹⁰⁰ wahlweise substituiert ist mit einem oder mehreren Substituenten, jeweils unabhängig gewählt aus der Gruppe bestehend aus F, Cl, CN, NO₂, - wahlweise substituiertem Alkyl, -O- (wahlweise substituiertes Alkyl), -C(O)H, -CONH₂, -NHSO₂CF₃, wahlweise substituiertem Heteroaryl, COOH, -Z¹⁰⁵-C(O)N(R)₂, -Z¹⁰⁵-N(R)-C(O)-Z²⁰⁰, -Z¹⁰⁵-N(R)-S(O)₂-Z²⁰⁰ und -Z¹⁰⁵-N(R)-C(O)-N(R)-Z²⁰⁰; Z¹⁰⁵ ist eine kovalente Bindung oder (C₁-C₆);

Z²⁰⁰ ist eine wahlweise substituierte Gruppe, gewählt aus der Gruppe bestehend aus (C₁-C₆), Phenyl und -(C₁-C₆), Phenyl;

Z¹¹⁰ und Z¹¹¹ sind jeweils unabhängig eine kovalente Bindung und

A ist O;

R_a ist Wasserstoff;

R₃ ist H;

R₂ ist -Z¹⁰¹-Z¹⁰²;

Z¹⁰¹ ist eine kovalente Bindung;

Z¹⁰² ist eine substituierte oder unsubstituierte Cycloalkylgruppe.

2. Eine Verbindung gemäß Anspruch 1, worin R₂ Cyclopentyl ist.

3. Eine Verbindung gemäß Anspruch 2, worin

Z¹⁰⁰ wahlweise substituiertes Phenyl ist, worin Z¹⁰⁰ wahlweise substituiert ist mit einem oder mehreren Substituenten, jeweils unabhängig gewählt aus der Gruppe bestehend aus F, COOH, NO₂, OMe, -COOMe, OCF₃ und CF₃.

4. Eine Verbindung gemäß Anspruch 2, worin

Z¹⁰⁰ ein wahlweise substituiertes Phenyl ist, worin Z¹⁰⁰ wahlweise substituiert ist mit einem oder mehreren Substituenten gewählt aus der Gruppe bestehend aus Alkyl, Alkoxy, Halo, Hydroxy und Alkoxy-carbonyl.

5. Eine Verbindung gemäß Anspruch 1, worin R² eine wahlweise substituierte Gruppe ist, gewählt aus der Gruppe bestehend aus Cyclobutyl und Cyclohexyl.

6. Eine Verbindung gemäß Anspruch 5, worin R² wahlweise substituiert ist mit einem oder mehreren Substituenten gewählt aus der Gruppe bestehend aus Hydroxy, Alkyl, Hydroxyalkyl, Carboxyalkyl und Phenylalkoxyalkyl.

7. Eine Verbindung gemäß Anspruch 1, worin R₁ 4-Phenoxyphenyl ist.

8. Eine Verbindung mit der Formel I gemäß Anspruch 1, worin R₁ = 4-Phenoxyphenyl, R₂ = Cyclopentyl und beide R₃ = H.

9. Verwendung einer Verbindung von Anspruch 1 oder eines physiologisch verträglichen Salzes davon zur Herstellung eines Medikaments zum Hemmen von einer oder mehreren Proteinkinaseaktivitäten in einem Patienten durch Verabreichen einer therapeutisch wirksamen Mengen an den Patienten.

10. Die Verwendung von Anspruch 9, worin die Protein-

kinase gewählt ist aus der Gruppe bestehend aus KDR, FGFR-1, PDGFR β , PDGFR α , IGF-1R, c-Met, Flt-1, Flt-4, TIE-2, TIE-1, Lck, Src, fyn, Lyn, Blk, hck, fgr und yes.


11. Die Verwendung von Anspruch 9, worin die Protein-kinase eine Proteinserin/Threoninkinase oder eine Proteintyrosinkinase ist.

12. Die Verwendung von Anspruch 10, worin die Protein-kinase Tie-2 ist.

13. Die Verwendung von Anspruch 9, worin die Protein-kinaseaktivität in die T-Zellaktivierung, B-Zellaktivierung, Mastzelldegranulation, Monozytenaktivierung, die Verstärkung einer entzündlichen Reaktion oder eine Kombination davon involviert ist.


Revendications

1. Composé de formule (I), ses mélanges racémique-diastéréomère, isomères optiques ou sels pharmaceutiquement acceptables,



où

R₁ est



Z¹⁰⁰ est un phényle éventuellement substitué,

où Z¹⁰⁰ est éventuellement substitué avec un ou plusieurs substituants choisi(s) chacun indépendamment à partir du groupe comportant F, Cl, CN, NO₂, -alkyle éventuellement substitué, -O-(alkyle éventuellement substitué), -C(O)H, -CONH₂, -NHSO₂CF₃, un hétéroaryle éventuelle-

ment substitué, COOH, -Z¹⁰⁵-C(O)N(R)₂, -Z¹⁰⁵-N(R)-C(O)-Z²⁰⁰, -Z¹⁰⁵-N(R)-S(O)₂-Z²⁰⁰, et -Z¹⁰⁵-N(R)-C(O)-N(R)-Z²⁰⁰; Z¹⁰⁵ est une liaison covalente ou (C₁-C₆); Z²⁰⁰ est un groupe éventuellement substitué choisi à partir du groupe comportant (C₁-C₆), un phényle et -(C₁-C₆)-phényle;

Z¹¹⁰ et Z¹¹¹ sont chacun indépendamment une liaison covalente et

A vaut 0;

R_a est un hydrogène;

R₃ est H;

R₂ est -Z¹⁰¹-Z¹⁰²;

Z¹⁰¹ est une liaison covalente;

Z¹⁰² est un groupe cycloalkyle substitué ou non substitué.

2. Composé selon la revendication 1, dans lequel R₂ est le cyclopentyle.

3. Composé selon la revendication 2, dans lequel

Z¹⁰⁰ est un phényle éventuellement substitué, où Z¹⁰⁰ est éventuellement substitué avec un ou plusieurs substituants choisi(s) chacun indépendamment à partir du groupe comportant F, COOH, NO₂, OMe, -COOMe, OCF₃ et CF₃.

4. Composé selon la revendication 2, dans lequel

Z¹⁰⁰ est un phényle éventuellement substitué, où Z¹⁰⁰ est éventuellement substitué avec un ou plusieurs substituants choisi(s) à partir du groupe comportant un alkyle, un alcoxy, un halo, un hydroxy et un alcoxycarbonyle.

5. Composé selon la revendication 1, dans lequel R² est un groupe éventuellement substitué choisi à partir du groupe comportant le cyclobutyle et le cyclohexyle.

6. Composé selon la revendication 5, dans lequel R² est éventuellement substitué avec un ou plusieurs substituant(s) choisi(s) à partir du groupe comportant un hydroxy, un alkyle, un hydroxyalkyle, un carboxyalkyle et un phénylalcoxyalkyle.

7. Composé selon la revendication 1, dans lequel R₁ est le 4-phénoxyphényle.

8. Composé de formule I selon la revendication 1, dans lequel R₁ = 4-phénoxyphényle, R₂ = cyclopentyle et les deux R₃ = H.

9. Utilisation d'un composé selon la revendication 1 ou d'un sel de ce composé physiologiquement acceptable dans la fabrication d'un médicament destiné à

inhiber une ou plusieurs activité(s) de protéine kinase chez un patient en lui en administrant une quantité thérapeutiquement efficace.

10. Utilisation selon la revendication 9 dans laquelle ladite protéine kinase est choisie à partir du groupe comportant KDR, FGFR-1, PDGFR β , PDGFR α , IGF-1R, c-Met, Flt-1, Flt-4, TIE-2, TIE-1, Lck, Src, Fyn, Lyn, Blk, hck, fgr et yes. 5

10

11. Utilisation selon la revendication 9 dans laquelle la protéine kinase est une protéine sérine-thréonine kinase ou une protéine tyrosine kinase.

12. Utilisation selon la revendication 10 dans laquelle la protéine kinase est Tie-2. 15

13. Utilisation selon la revendication 9 dans laquelle l'activité de protéine kinase est impliquée dans l'activation des cellules T, l'activation des cellules B, la dégranulation des mastocytes, l'activation des monocytes, la potentialisation d'une réponse inflammatoire ou une combinaison de ceux-ci. 20

25

30

35

40

45

50

55

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 9714696 W [0015]
- WO 9807832 A, Witzenbichler [0015]
- US 4966849 A [0020]
- WO 9410202 A [0020]
- WO 9403427 A [0020] [0021]
- WO 9221660 A [0020] [0021]
- WO 9115495 A [0020] [0021]
- WO 9414808 A [0020] [0021]
- US 5330992 A [0020]
- WO 9220642 A [0021]
- US 5217999 A [0021]
- US 5302606 A [0021]
- EP 0566266 A1 [0021]
- WO 9734876 A [0021]
- WO 9722596 A [0021]
- WO 9742187 A [0021] [0139]
- WO 9740830 A [0022]
- WO 9740831 A [0022]

Non-patent literature cited in the description

- SCHLESSINGER ; ULLRICH. *Neuron*, 1992, vol. 9, 383-391 [0003]
- YARDEN ; ULLRICH. *Ann. Rev. Biochem.*, 1988, vol. 57, 433-478 [0005]
- ULLRICH ; SCHLESSINGER. *Cell*, 1990, vol. 61, 243-254 [0005]
- SCHLESSINGER ; ULLRICH. *Neuron*, 1992, vol. 9, 1-20 [0005]
- FANTL et al. *Cell*, 1992, vol. 69, 413-423 [0006]
- SONGYANG et al. *Mol. Cell. Biol.*, 1994, vol. 14, 2777-2785 [0006]
- SONGYANG et al. *Cell*, 1993, vol. 72, 767-778 [0006] [0006]
- KOCH et al. *Science*, 1991, vol. 252, 668-678 [0006]
- SHOELSON. *Curr. Opin. Chem. Biol.*, 1997, vol. 1 (2), 227-234 [0006]
- COWBURN. *Curr. Opin. Struct. Biol.*, 1997, vol. 7 (6), 835-838 [0006]
- SONGYANG et al. *Cell*, vol. 72, 767-778 [0006]
- MUSTONEN ; ALITALO. *J. Cell Biol.*, 1995, vol. 129, 895-898 [0007]
- TERMAN et al. *Oncogene*, 1991, vol. 6, 1677-83 [0007]
- OELRICHS et al. *Oncogene*, 1993, vol. 8 (1), 11-15 [0007]
- MATTHEWS et al. *Proc. Natl. Acad. Sci. USA*, 1991, vol. 88, 9026-30 [0007]
- TERMAN et al. *Biochem. Biophys. Res. Comm.*, 1991, vol. 187, 1579-86 [0007]
- TERMAN et al. *Biochem. Biophys. Res. Comm.*, 1992, vol. 187, 1579-86 [0007]
- SARZANI ; MILLAUER et al. *Cell*, 1993, vol. 72, 835-846 [0007]
- DEVRIES et al. *Science*, 1992, vol. 255, 989-991 [0008]
- SHIBUYA et al. *Oncogene*, 1990, vol. 5, 519-524 [0008]
- KLAGSBURN ; D'AMORE. *Cytokine & Growth Factor Reviews*, 1996, vol. 7, 259-270 [0008]
- JAKEMAN et al. *Endocrinology*, 1993, vol. 133, 848-859 [0009]
- KOLCH et al. *Breast Cancer Research and Treatment*, 1995, vol. 36, 139-155 [0009]
- FERRARA et al. *Endocrine Reviews*, 1997, vol. 18 (1), 4-25 [0009]
- FERRARA et al. *Regulation of Angiogenesis*, 1997, 209-232 [0009]
- CONNOLLY et al. *J. Biol. Chem.*, 1989, vol. 264, 20017-20024 [0009]
- BROWN et al. *Regulation of Angiogenesis*, 1997, 233-269 [0009]
- FERRARA et al. *J. Cell. Biochem.*, 1991, vol. 47, 211-218 [0009]
- KORPELAINE ; ALITALO. *Curr. Opin. Cell Biol.*, 1998, 159-164 [0010]
- PARK et al. *J. Biol. Chem.*, 1994, vol. 269, 25646-54 [0011]
- MAGLIONE et al. *Oncogene*, 1993, vol. 8, 925-31 [0011]
- MIGDAL et al. *J. Biol. Chem.*, vol. 273 (35), 22272-22278 [0011]
- PEPPER et al. *Proc. Natl. Acad. Sci. U. S. A.*, 1998, vol. 95 (20), 11709-11714 [0012]
- LYMBOUSSAKI et al. *Am. J. Pathol.*, 1998, vol. 153 (2), 395-403 [0013]
- WITZENBICHLER et al. *Am. J. Pathol.*, 1998, vol. 153 (2), 381-394 [0013]
- RISTIMAKI et al. *J. Biol. Chem.*, 1998, vol. 273 (14), 8413-8418 [0013]
- ACHEN et al. *Proc. Natl. Acad. Sci. U. S. A.*, 1998, vol. 95 (2), 548-553 [0014]

- MEYER et al. *EMBO J.*, 1999, vol. 18 (2), 363-374 [0016]
- OGAWA et al. *J. Biol. Chem.*, 1998, vol. 273 (47), 31273-31282 [0016]
- STACKER, S.A ; VITALI, A ; DOMAGALA, T ; NICE, E ; WILKS, A.F. Angiogenesis and Cancer. Conference, Amer. Assoc. Cancer Res, January 1998, vol. 40, 118-120 [0017]
- ORLANDO, FL ; WILLIAMS. *Diabetologia*, 1997, vol. 40, 118-120 [0017]
- BOLEN. *Oncogene*, 1993, vol. 8, 2025-2031 [0018]
- KENDALL ; THOMAS. *Proc. Natl. Acad. Sci*, 1994, vol. 90, 10705-09 [0020]
- KIM et al. *Nature*, 1993, vol. 362, 841-844 [0020]
- JELLINEK et al. *Biochemistry*, vol. 33, 10450-56 [0020]
- TAKANO et al. *Mol. Bio. Cell*, 1993, vol. 4, 358A [0020]
- KINSELLA et al. *Exp. Cell Res*, 1992, vol. 199, 56-62 [0020]
- WRIGHT et al. *J. Cellular Phys*, 1992, vol. 152, 448-57 [0020]
- MARIANI et al. *Proc. Am. Assoc. Cancer Res.*, 1994, vol. 35, 2268 [0020]
- *Expert Opin. Ther. Pat*, 1998, vol. 8 (4), 475-478 [0021]
- MYERSON et al. *EMBO Journal*, 1992, vol. 11, 2909-2917 [0032]
- DRAETTA. *Trends in Cell Biology*, 1993, vol. 3, 287-289 [0032] [0032] [0032]
- MURRAY ; KIRSCHNER. *Nature*, 1989, vol. 339, 275-280 [0032] [0032] [0032]
- SOLOMON et al. *Molecular Biology of the Cell*, 1992, vol. 3, 13-27 [0032] [0032] [0032]
- DUCOMMUN et al. *EMBO Journal*, 1991, vol. 10, 3311-3319 [0032]
- GAUTIER et al. *Nature*, 1989, vol. 339, 626-629 [0032]
- GOULD ; NURSE. *Nature*, 1989, vol. 342, 39-45 [0032]
- KREK ; NIGG. *EMBO Journal*, 1991, vol. 10, 3331-3341 [0032]
- SOLOMON et al. *Cell*, 1990, vol. 63, 1013-1024 [0032]
- PINES. *Trends in Biochemical Sciences*, 1993, vol. 18, 195-197 [0032]
- SHERR. *Cell*, 1993, vol. 73, 1059-1065 [0032]
- MATSUSHIMA et al. *Molecular & Cellular Biology*, 1994, vol. 14, 2066-2076 [0032]
- OHTSUBO ; ROBERTS. *Science*, 1993, vol. 259, 1908-1912 [0032]
- QUELLE et al. *Genes & Development*, 1993, vol. 7, 1559-1571 [0032]
- RESNITZKY et al. *Molecular & Cellular Biology*, 1994, vol. 14, 1669-1679 [0032]
- GIRARD et al. *Cell*, 1991, vol. 67, 1169-1179 [0032] [0032]
- PAGANO et al. *EMBO Journal*, 1992, vol. 11, 961-971 [0032] [0032]
- ROSENBLATT et al. *Proceedings of the National Academy of Science USA*, 1992, vol. 89, 2824-2828 [0032] [0032]
- WALKER ; MALLER. *Nature*, 1991, vol. 354, 314-317 [0032] [0032]
- ZINDY et al. *Biochemical & Biophysical Research Communications*, 1992, vol. 182, 1144-1154 [0032] [0032]
- PINES. *Current Opinion in Cell Biology*, 1992, vol. 4, 144-148 [0032]
- LEES. *Current Opinion in Cell Biology*, 1995, vol. 7, 773-780 [0032]
- HUNTER ; PINES. *Cell*, 1994, vol. 79, 573-582 [0032]
- D. MUKHOPEDHYAY et al. *Cancer Res.*, 1998, vol. 58, 1278-1284 [0053]
- *Genes and Devel*, 1999, vol. 13, 1055-1066 [0060]
- Remington's Pharmaceutical Sciences. Mack Publishing Co, [0064]
- Z. SONGYANG et al. *Nature*, vol. 373, 536-539 [0102]
- Enzyme-Linked Immunosorbent Assay. VOLLER et al. *Manual of Clinical Immunology*. 1980, 359-371 [0111]
- YASUDA, I ; KIRSHIMOTO, A ; TANAKA, S ; TOMINAGA, M ; SAKURAI, A ; NISHIZUKA, Y. *Biochemical and Biophysical Research Communication*, 1990, vol. 3 (166), 1220-1227 [0124]
- *Current Protocols in Immunology*, vol. 2, 7.10.1-7.11.2 [0127]
- *FASEB J*, 1991, vol. 5, 2560-2566 [0131]
- *Lab. Invest*, 1981, vol. 4 (3), 278 [0131]
- *J. Immunol*, 1991, vol. 146 (4), 1163-8 [0131]
- *J. Immunol*, vol. 142 (7), 2237-2243 [0132]
- *Ann. Rev. Immunol*, 1992, vol. 10, 333-58 [0134]
- *Transplantation*, 1994, vol. 57 (12), 1701-17 [0134]
- *Am.J.Anat*, 1963, vol. 113, 273 [0134]
- CULLINAN-BOVE ; KOSS. *Endocrinology*, 1993, vol. 133, 829-837 [0139]
- PASSANITI, A et al. *Lab. Investig*, 1992, vol. 67 (4), 519-528 [0141]
- *Anat. Rec*, 1997, vol. 249 (1), 63-73 [0141]
- *Int. J. Cancer*, 1995, vol. 63 (5), 694-701 [0141]
- *Vasc. Biol*, 1995, vol. 15 (11), 1857-6 [0141]